[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2453
1. Zhang LL, Shao SL, Wu Y: [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chin J Cancer; 2010 Jan;29(1):25-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The positive rate of OPN associated with a higher rate of lymph node metastasis (P<0.05), but did not relate to age and histologic type.
  • The positive rate of B7-H4 were significantly higher in ovarian serous carcinoma than in the mucinous carcinoma (P<0.05), but did not relate to age and lymph node metastasis.
  • CONCLUSION: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038306.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 106441-73-0 / Osteopontin; Ovarian epithelial cancer
  •  go-up   go-down


2. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • Specific information regarding intraductal papillary mucinous neoplasm (IPMN) recurrence is limited because most series are small and the follow-up interval is short.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Tomimaru Y, Ishikawa O, Ohigashi H, Eguchi H, Yamada T, Sasaki Y, Kishi K, Takachi K, Noura S, Miyashiro I, Ohue M, Yano M, Imaoka S: Intraductal papillary-mucinous carcinoma of the pancreas with tumor thrombus in the portal vein: a report of two cases. Hepatogastroenterology; 2007 Jul-Aug;54(77):1585-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous carcinoma of the pancreas with tumor thrombus in the portal vein: a report of two cases.
  • Intraductal papillary-mucinous carcinoma (IPMC) is a recently recognized pancreatic tumor and this is the first report to present two patients with IPMC complicating tumor thrombi in the portal vein.
  • Owing to this information, the presence of tumor thrombus was investigated and correctly identified during laparotomy, and it was completely removable together with the primary pancreatic tumor.
  • The resected tumors showed expansive growth because mucin and tumor tissues rose up when they were cut.
  • Microscopically, the tumor was diagnosed as adenocarcinoma without ovarian-like stroma, and the final diagnosis of branch type of IPMC was made for the two patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Carcinoma, Pancreatic Ductal / secondary. Neoplastic Cells, Circulating. Pancreatic Neoplasms / pathology. Portal Vein

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708306.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Larrousse C, Brasseur P, Sukkarieh F: [Port-site metastasis following laparoscopic radical prostatectomy for mucinous adenocarcinoma of the prostate]. J Radiol; 2005 Mar;86(3):337-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis following laparoscopic radical prostatectomy for mucinous adenocarcinoma of the prostate].
  • [Transliterated title] Métastase orificielle après prostatectomie radicale coelioscopique pour un adénocarcinome mucineux de la prostate.
  • A 52-year-old man underwent laparoscopic radical prostatectomy for mucinous adenocarcinoma.
  • Eight months later, an abdominal wall metastasis developed at the trocar site through which the laparoscope had been introduced.
  • To our knowledge, it is the first reported case of port site metastasis after laparoscopic radical prostatectomy.
  • [MeSH-major] Abdominal Neoplasms / secondary. Abdominal Wall. Adenocarcinoma, Mucinous / secondary. Laparoscopy / adverse effects. Neoplasm Seeding. Prostatectomy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908875.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Jones NB, Hatzaras I, George N, Muscarella P, Ellison EC, Melvin WS, Bloomston M: Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience. HPB (Oxford); 2009 Dec;11(8):664-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience.
  • We sought to review our experience with the surgical management of cystic neoplasms of the pancreas to determine pre-operative clinical indicators of malignancy or premalignant (i.e. mucinous) lesions.
  • Invasive adenocarcinoma was identified in 35 whereas 79 had benign lesions.
  • Mucinous lesions were considered premalignant and consisted of 29 intraductal papillary mucinous neoplasms (IPMN) and 17 mucinous cystic neoplasms (MCN).
  • Mucinous lesions with or without associated cancer were more likely to be symptomatic and present with elevated serum carbohydrate antigen (CA)19-9 levels.
  • Using multivariate logistic regression, size and elevated CA19-9 were predictors of malignancy whereas male gender and size were predictors of mucinous lesions with or without malignancy.
  • Size, however, was not an accurate test to determine premalignant or malignant lesions using area under the ROC curve analysis whereas CA19-9 performed the best regardless of gender or lesion location.
  • CONCLUSIONS: Based upon our single institution experience with resection of cystic neoplasms of the pancreas, we advocate an aggressive surgical approach to any patient with a cystic neoplasm of the pancreas and associated elevated CA19-9.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495634.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2799619
  •  go-up   go-down


6. Kubosawa H, Iwasaki H, Kuzuta N, Suzuki H, Iura H: Adenocarcinoma with peritoneal dissemination secondary to multiple mature teratomas of the omentum. Gynecol Oncol; 2006 Jun;101(3):534-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma with peritoneal dissemination secondary to multiple mature teratomas of the omentum.
  • CASE: A 62-year-old woman with a history of bilateral salpingo-oophorectomy due to ectopic pregnancy was found to have multiple cystic teratomas of the omentum.
  • There was a histologic evidence of a sequential transition from benign through borderline to obviously invasive adenocarcinoma within the lining of the cysts as well as peritoneal dissemination.
  • CONCLUSION: We defined the present case as malignant transformation of a mature teratoma, but have no evidence whatsoever for the origin of multiple mature teratomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Neoplasms, Multiple Primary / pathology. Omentum / pathology. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488467.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Lim SJ, Feig BW, Wang H, Hunt KK, Rodriguez-Bigas MA, Skibber JM, Ellis V, Cleary K, Chang GJ: Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. Ann Surg Oncol; 2008 Jan;15(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients underwent resection and SLN mapping with 1% isosulfan blue and (m99)Tc sulfur colloid injection.
  • Overall survival for patients with IHC-positive disease was evaluated by Kaplan-Meier analysis and the log rank test.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Isosulfan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jan;15(1):1-3 [17929100.001]
  • (PMID = 17985187.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Rosaniline Dyes; 39N9K8S2A4 / iso-sulfan blue; 68238-35-7 / Keratins
  •  go-up   go-down


8. Ikuta S, Aihara T, Yasui C, Iida H, Yanagi H, Mitsunobu M, Kakuno A, Yamanaka N: Large mucinous cystic neoplasm of the pancreas associated with pregnancy. World J Gastroenterol; 2008 Dec 21;14(47):7252-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mucinous cystic neoplasm of the pancreas associated with pregnancy.
  • Mucinous cystic neoplasms (MCNs) of the pancreas occur mostly in females and are potentially sex hormone-sensitive.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Pancreatic Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1986 Jul;73(7):591 [3730799.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1230-5 [7535275.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Pancreas. 2005 Mar;30(2):186-8 [15714143.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):383-9 [16111956.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(6):494-7 [16365826.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2236-45 [17103100.001]
  • [Cites] Pancreas. 2007 May;34(4):470-3 [17446848.001]
  • [Cites] Pancreas. 2007 May;34(4):474-6 [17446849.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] JOP. 2007;8(5):553-63 [17873459.001]
  • [Cites] Surg Today. 2007;37(11):1013-7 [17952538.001]
  • [Cites] Tumori. 1990 Jun 30;76(3):294-5 [2368178.001]
  • (PMID = 19084943.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2776886
  •  go-up   go-down


9. Stewart CJ, Crook ML, Leung YC, Platten M: Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod Pathol; 2009 May;22(5):725-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands.
  • Endometrial adenocarcinomas may show a distinctive pattern of invasion characterized by the presence of microcystic, elongated and fragmented glands, often most evident along the advancing tumor margin.
  • Earlier, we have shown that these changes appear restricted to low-grade endometrioid carcinomas, many of which show focal mucinous differentiation and lymphovascular space invasion.
  • In this study, we have examined immunoreactivity for the cell cycle regulatory proteins cyclin D1, p16 and beta-catenin in 22 endometrial carcinomas, specifically comparing the results in conventional tumor areas and in foci in which the glands exhibited microcystic, elongated and fragmented appearances.
  • The heterogeneous expression of cell cycle regulatory proteins within endometrial adenocarcinoma illustrates the importance of assessing microanatomical variations in immunoreactivity, particularly at the advancing margin of tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Cycle Proteins / biosynthesis. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19270644.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / beta Catenin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


10. Westphalen AC, Coakley FV, Joe BN: Radiological reasoning: 88-year-old man with abdominal pain and dilated biliary tree and pancreatic duct. AJR Am J Roentgenol; 2010 Jun;194(6 Suppl):S46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Abdominal Pain / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Pneumonia / diagnosis
  • [MeSH-minor] Aged, 80 and over. Ampulla of Vater / pathology. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Diagnosis, Differential. Dilatation, Pathologic. Endoscopy, Gastrointestinal. Endosonography. Humans. Incidental Findings. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489116.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Zohny SF, Fayed ST: Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol; 2010 Dec;27(4):1246-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.
  • Ovarian cancer remains a highly lethal disease.
  • The aim of the present study was to evaluate the usefulness of measuring serum matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) in comparison with serum cancer antigen 125 (CA 125) for diagnosis of epithelial ovarian cancer (EOC).
  • Our data indicate that serum MMP-7, CCL18 and CCL11, in combination with CA 125 could be useful in diagnosis of EOC.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Chemokine CCL11 / blood. Chemokines, CC / blood. Matrix Metalloproteinase 7 / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Prognosis. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):179-87 [10228898.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):374-82 [18584856.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1723-34 [9137096.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66 [17255266.001]
  • [Cites] Open Clin Cancer J. 2008 Feb 06;2:7-12 [18665245.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Immunity. 1999 Feb;10(2):137-42 [10072066.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2647-56 [19351767.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):143-52 [11322833.001]
  • [Cites] Mol Cancer Res. 2006 Nov;4(11):831-41 [17114341.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67 [17828470.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2385-91 [17438097.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24584-93 [11978786.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):273-86 [15781314.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):19-31 [15523695.001]
  • [Cites] J Leukoc Biol. 2005 Jul;78(1):14-26 [15784687.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):879-88 [16152587.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]
  • [Cites] Int Arch Allergy Immunol. 2000 May;122 Suppl 1:54-8 [10867510.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] J Leukoc Biol. 2001 May;69(5):785-93 [11358988.001]
  • [Cites] PLoS One. 2008 Jul 09;3(7):e2633 [18612378.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):713-7 [9192897.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2499-505 [14602136.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):40-8 [11426960.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):92-6 [16278009.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1411-8 [9570561.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):799-809 [9533550.001]
  • [Cites] Biomark Med. 2009 Jun 1;3(3):275-288 [19684876.001]
  • (PMID = 19937162.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CCL11 protein, human; 0 / CCL18 protein, human; 0 / Chemokine CCL11; 0 / Chemokines, CC; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


12. Van Elssen CH, Frings PW, Bot FJ, Van de Vijver KK, Huls MB, Meek B, Hupperets P, Germeraad WT, Bos GM: Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology; 2010 Oct;57(4):597-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aberrantly glycosylated Mucin-1 in ovarian cancer.
  • AIMS:   Mucin 1 (MUC1) is an important tumour-associated antigen (TAA), both overexpressed and aberrantly glycosylated in adenocarcinomas.
  • The aim of this study was to examine the MUC1-glycosylation status of primary ovarian adenocarcinomas and metastatic lesions.
  • METHODS AND RESULTS:   Paraffin-embedded tissue sections of 37 primary ovarian adenocarcinomas representing all histotypes (22 serous, five mucinous, two clear-cell, eight endometrioid), four serous borderline tumours with intraepithelial carcinoma, seven sections of ovarian endometriosis and 13 metastatic lesions were analysed by immunohistochemistry.
  • Of primary tumours, 76% expressed the differentiation-dependent glycoform and 84% the cancer-associated glycoform (Tn/Sialyl-Tn-epitopes).
  • CONCLUSIONS:   The underglycosylated MUC1 epitopes are expressed by all histotypes of primary ovarian adenocarcinomas, by the vast majority of metastatic lesions and by possible ovarian cancer precursor lesions, but not by normal ovarian tissue.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucin-1 / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20955385.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Mucin-1
  •  go-up   go-down


13. Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM: The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol; 2008 Mar;108(3):561-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether eukaryotic elongation factor 1 alpha 2 (eEF1A2), a transforming gene previously shown to be highly expressed in primary human ovarian tumours, is a prognostic marker.
  • METHODS: We have used an antibody specific for eEF1A2 to measure eEF1A2 protein expression in 500 primary ovarian tumours in a tissue microarray.
  • We have also ectopically expressed eEF1A2 in SK-OV-3 cells, a clear cell carcinoma line that does not normally express eEF1A2.
  • RESULTS: We have shown that eEF1A2 has high expression levels in approximately 30% of all primary ovarian tumours.
  • 50% of serous tumours, 30% of endometrioid, 19% of mucinous and 8% of clear cell tumours highly express eEF1A2.
  • Ectopic expression of eEF1A2 in the SK-OV-3 clear cell carcinoma line enhances their in vitro proliferative capacity and ability to form tumour-like spheroids in hanging drop culture.
  • CONCLUSIONS: eEF1A2 is highly expressed in ovarian carcinomas.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Antibodies / analysis. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cell Proliferation. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Flow Cytometry. Humans. Ontario / epidemiology. Predictive Value of Tests. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164751.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / EEF1A2 protein, human; 0 / Peptide Elongation Factor 1
  •  go-up   go-down


14. Jiménez-Ayala M: Micropapillary carcinoma and mucinous carcinoma with a micropapillary pattern. Acta Cytol; 2007 Jan-Feb;51(1):1-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma and mucinous carcinoma with a micropapillary pattern.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Acta Cytol. 2007 Jan-Feb;51(1):25-32 [17328491.001]
  • (PMID = 17328486.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


15. Chabowska AM, Sulkowska M, Chabowski A, Wincewicz A, Koda M, Sulkowski S: Erythropoietin and erythropoietin receptor in colorectal cancer. Int J Surg Pathol; 2008 Jul;16(3):269-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate immunohistochemically the expression of erythropoietin and erythropoietin receptor in 136 primary colorectal cancers with a correlation to different anatomo-clinical features.
  • Erythropoietin and erythropoietin receptor expressions were statistically higher in adenocarcinomas versus mucinous carcinomas (P = .05 and P = .03, respectively) and in moderately (G2) versus poorly differentiated (G3) tumors (P = .001 and P = .02, respectively).
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Colorectal Neoplasms / metabolism. Erythropoietin / metabolism. Receptors, Erythropoietin / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487221.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Erythropoietin; 11096-26-7 / Erythropoietin
  •  go-up   go-down


16. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME: Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev; 2006 Oct;15(10):1899-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
  • BACKGROUND: Historically, female breast carcinoma has been viewed as an etiologically homogeneous disease associated with rapidly increasing incidence rates until age 50 years, followed by a slower rate of increase among older women.
  • MATERIALS AND METHODS: To determine if different age incidence patterns reflect etiologic heterogeneity (more than one breast cancer type within the general breast carcinoma), we applied "smoothed" age histograms at diagnosis (density plots) and a two-component statistical mixture model to all breast carcinoma cases (n = 270,124) in the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.
  • RESULTS: A bimodal age distribution at diagnosis provided a better fit to the data than a single density for all breast carcinoma populations, except for medullary carcinoma.
  • Medullary carcinomas showed a single age distribution at diagnosis irrespective of race and/or ER expression.
  • CONCLUSIONS: Distinct age-specific incidence patterns reflected bimodal breast cancer populations for breast carcinoma overall as well as for histopathologic subtypes, race, and ER expression.
  • The one exception was medullary carcinoma.
  • Of note, medullary carcinomas are rare tumors, which are associated with germ-line mutations in the BRCA1 gene.
  • These descriptive and model-based results support emerging molecular data, suggesting two main types of breast carcinoma in the overall breast cancer population.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Breast Neoplasms / epidemiology. Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / pathology. Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / pathology. Carcinoma, Medullary / epidemiology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Registries. SEER Program. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17035397.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


17. Buttarelli M, Houvenaeghel G, Lelièvre L, Jacquemier J, Guiramand J, Delpero JR: [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?]. Ann Chir; 2006 Oct;131(8):431-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?].
  • [Transliterated title] Une exentération pelvienne postérieure avec anastomose est-elle faisable et justifiée dans le traitement des cancers de l'ovaire à un stade évolué?
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Endometrioid / surgery. Carcinosarcoma / surgery. Colon / surgery. Ovarian Neoplasms / surgery. Pelvic Exenteration. Rectum / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Colostomy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystectomy. Feasibility Studies. Female. Humans. Hysterectomy. Ileostomy. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Ovary / pathology. Preoperative Care. Quality of Life. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707093.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Blanc B, Sauvanet A, Couvelard A, Pessaux P, Dokmak S, Vullierme MP, Lévy P, Ruszniewski P, Belghiti J: [Limited pancreatic resections for intraductal papillary mucinous neoplasm]. J Chir (Paris); 2008 Nov-Dec;145(6):568-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limited pancreatic resections for intraductal papillary mucinous neoplasm].
  • INTRODUCTION: For non-invasive intraductal papillary and mucinous neoplasm (IPMN) with limited extent, pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) seem excessive due to the risk of pancreatic insufficiency.
  • Indications for surgery were pain/pancreatitis (44%), suspicion of main duct involvement (28%), mural nodules in branch duct (14%), branch duct>30 mm (8%) or suspicion of mucinous cystadenoma (6%).
  • Two patients (5%) developed de novo diabetes (one after EN combined with DP) and a third patient developed worsening of pre-existing diabetes plus exocrine insufficiency.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106888.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Ball E, Morris-Stiff G, Coxon M, Lewis MH: Mucinous adenocarcinoma presenting as an isolated sternal metastasis. World J Surg Oncol; 2007;5:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma presenting as an isolated sternal metastasis.
  • BACKGROUND: As a result of improvements in diagnostic accuracy, the primary source of the tumour is identified in more than 99% of cases presenting with a malignancy.
  • Whilst the axial skeleton is a common site of metastases, the sternum is rarely affected, especially by isolated metastases.
  • CASE PRESENTATION: We report a case of a 68 year old male who was referred to the surgical outpatient clinic with a six month history of sternal pain.
  • The patient was known to have essential thrombocythaemia, which had recently transformed into acute myeloid leukaemia but a sternal biospy showed mucinous adenocarcinoma.
  • He had not localising symptoms and full evaluation failed to localise the primary tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2001 Jun;42(3):411-4 [11398042.001]
  • [Cites] Ann Intern Med. 1986 Apr;104(4):547-53 [3006571.001]
  • [Cites] Thorax. 1977 Aug;32(4):444-8 [929487.001]
  • (PMID = 17892541.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2048510
  •  go-up   go-down


20. Kobayashi K, Sadakari Y, Ohtsuka T, Takahata S, Nakamura M, Mizumoto K, Tanaka M: Factors in intraductal papillary mucinous neoplasms of the pancreas predictive of lymph node metastasis. Pancreatology; 2010;10(6):720-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors in intraductal papillary mucinous neoplasms of the pancreas predictive of lymph node metastasis.
  • BACKGROUND: Little is known about the frequency of lymph node metastasis (LNM) in intraductal papillary mucinous neoplasms (IPMNs), and we have not been able to determine how much lymph node dissection is necessary in individual cases.
  • Multivariate analysis demonstrated that only an imaging finding for invasive tumor was an independent significant predictive factor.
  • Positive and negative predictive values of the imaging finding of invasive IPMNs for LNM were 50 and 98%, respectively.
  • CONCLUSIONS: Standard lymph node dissection would be recommended in patients with IPMNs with mural nodules demonstrating preoperative imaging findings for invasive carcinomas. and IAP.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Carcinoma, Pancreatic Ductal / secondary. Cystadenocarcinoma, Mucinous / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21242713.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Murthy RV, Arbman G, Gao J, Roodman GD, Sun XF: Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res; 2005 Mar 15;11(6):2293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We investigated legumain expression in 164 primary colorectal cancers, 34 corresponding distant normal mucosa samples, 89 adjacent normal mucosa samples, and 33 lymph node metastases using immunohistochemistry.
  • RESULTS: Legumain expression was increased in primary tumors compared with distant or adjacent normal mucosa (P < 0.05), but there was no significant change between primary tumors and metastases (P > 0.05).
  • Legumain expression was positively related to poorer differentiation/mucinous carcinoma (P = 0.04), higher degree of necrosis (P = 0.03) and apoptosis (P < 0.0001), positive proliferating cell nuclear antigen (P < 0.0001) and p53 expression (P = 0.049), and had a positive tendency towards stromelysin 3 (P = 0.058) and PINCH positivity (P = 0.05).
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788679.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.34 / asparaginylendopeptidase
  •  go-up   go-down


22. Park S, Koo J, Kim JH, Yang WI, Park BW, Lee KS: Clinicopathological characteristics of mucinous carcinoma of the breast in Korea: comparison with invasive ductal carcinoma-not otherwise specified. J Korean Med Sci; 2010 Mar;25(3):361-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous carcinoma of the breast in Korea: comparison with invasive ductal carcinoma-not otherwise specified.
  • Clinicopathological characteristics and prognostic factors of mucinous carcinoma (MC) were compared with invasive ductal carcinoma-not otherwise specified (IDC-NOS).
  • The median age at diagnosis was 45 yr in MC and 47 yr in IDC-NOS, respectively.
  • MC showed favorable characteristics including less involvement of lymph node, lower stage, more expression of estrogen receptors, less HER-2 overexpression and differentiated grade, and better 10-yr disease-free survival (DFS) and overall survival (OS) (86.1% and 86.3%, respectively) than IDC-NOS (74.7% and 74.9%, respectively).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / pathology. Disease-Free Survival. Female. Genes, erbB-2. Humans. Korea. Lymphatic Metastasis. Mammography. Middle Aged. Prognosis. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Radiol. 2000 Jul;35(1):39-43 [10930764.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1442-8 [10334529.001]
  • [Cites] Arch Surg. 2006 Feb;141(2):155-60 [16490892.001]
  • [Cites] Clin Radiol. 2006 May;61(5):423-30 [16679116.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):209-14 [16862450.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):127-35 [17330844.001]
  • [Cites] J Med Screen. 2007;14(4):205-9 [18078566.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):11-9 [17873114.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):161-79 [18443206.001]
  • [Cites] Breast Cancer Res Treat. 2008 Oct;111(3):541-7 [18026874.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):65-70 [11029773.001]
  • [Cites] AJR Am J Roentgenol. 2003 Apr;180(4):935-40 [12646432.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):832-5 [12766589.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):27-30; discussion 31 [14718270.001]
  • [Cites] Am J Surg. 2004 Apr;187(4):528-32 [15041505.001]
  • [Cites] Breast. 2004 Aug;13(4):297-306 [15325664.001]
  • [Cites] Am J Clin Pathol. 1971 Mar;55(3):355-63 [4323690.001]
  • [Cites] Histopathology. 1980 Nov;4(6):613-30 [6254868.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):989-96 [2827884.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):702-11 [8017565.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):162-7 [7898111.001]
  • [Cites] Lancet. 1996 Mar 30;347(9005):881-2 [8622398.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1046-52 [16175185.001]
  • (PMID = 20191033.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2826751
  • [Keywords] NOTNLM ; Adenocarcinoma, Mucinous / Breast / Korea / Prognosis
  •  go-up   go-down


23. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY: Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer; 2006 Oct 23;95(8):1087-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mitochondrial DNA (mtDNA) content in ovarian carcinomas was assessed by quantitative PCR.
  • However, the average mtDNA copy number in pathological low-grade tumours was over two-fold higher than that in high-grade carcinomas (P=0.012).
  • Moreover, type I carcinomas also had a significantly higher mtDNA copy number than in type II carcinomas (P=0.019).
  • Change in mtDNA content might be an important genetic event in the progression of ovarian carcinomas.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. DNA Replication / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):697-701 [12915881.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):378-81 [12893203.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):71-8 [15013701.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Med Genet. 2004 May;41(5):e65 [15121793.001]
  • [Cites] FEBS Lett. 2004 Dec 3;578(1-2):198-202 [15581641.001]
  • [Cites] Hum Reprod. 2005 Mar;20(3):593-7 [15608038.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):104-10 [15921730.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):19-28 [15892105.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3482-92 [16163384.001]
  • [Cites] Biochem J. 2000 Jun 1;348 Pt 2:425-32 [10816438.001]
  • [Cites] Eur J Appl Physiol. 2000 Aug;82(5-6):407-12 [10985594.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1299-304 [11245424.001]
  • [Cites] Trends Genet. 2001 Apr;17(4):199-205 [11275325.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):759-68 [12016148.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2260-5 [12114429.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6470-4 [12438238.001]
  • [Cites] Exp Physiol. 2003 Jan;88(1):109-19 [12525860.001]
  • [Cites] Exp Physiol. 2003 Jan;88(1):121-8 [12552316.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):90-5 [12556965.001]
  • [Cites] Hum Reprod. 2003 Mar;18(3):550-6 [12615823.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • (PMID = 17047655.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ PMC2360719
  •  go-up   go-down


24. Acs G: Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol; 2005 Jun;123 Suppl:S13-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous and mucinous borderline (low malignant potential) tumors of the ovary.
  • Serous tumors with a micropapillary and/or cribriform growth pattern seem to be more frequently bilateral and exophytic and manifest at an advanced stage with a higher incidence of invasive implants than typical SBOTs.
  • Molecular data suggest that such tumors may represent an intermediate stage in the typical SBOT-invasive low-grade serous carcinoma progression.
  • Limited experience with endocervical (müllerian)-type mucinous borderline tumors shows a possible relation to SBOTs in clinicopathologic features and biologic behavior Intestinal-type mucinous borderline ovarian tumors (I-MBOTs) and well-differentiated mucinous carcinomas manifest at stage I in most cases; the prognosis is excellent.
  • Mucinous tumors associated with pseudomyxoma peritonei are almost always secondary to similar tumors of the appendix or other gastrointestinal sites and should not be diagnosed as high-stage I-MBOTs.
  • Rare primary ovarian mucinous tumors associated with pseudomyxoma peritonei are those arising in mature cystic teratomas.
  • Advanced-stage ovarian mucinous carcinomas typically show frank, infiltrative-type invasion; the prognosis is poor.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / classification. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Ovarian Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100867.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 296
  •  go-up   go-down


25. Conlon KC: Intraductal papillary mucinous tumors of the pancreas. J Clin Oncol; 2005 Jul 10;23(20):4518-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas.
  • Intraductal papillary mucinous neoplasms of the pancreas (IPMNs) are increasingly recognized in clinical practice.
  • They are a unique clinicopathologic entity that is characterized by mucin production, cystic dilation of the pancreatic ducts, and intraductal papillary growth.
  • Histologically, they may demonstrate a spectrum of cellular atypia ranging from minimal mucinous hyperplasia to frank invasive carcinoma.
  • Similar to invasive ductal adenocarcinoma of the pancreas, patients with IPMN generally present in the seventh or eighth decade of life with the head of the gland being the predominant disease site.
  • Traditionally, the diagnosis was made following an endoscopic retrograde cholangiopancreatography.
  • The aim should be to resect all gross disease while attempting to achieve a negative surgical margin, which in the majority of cases can be achieved by a partial pancreatectomy.
  • The disease seems to be somewhat indolent with resection of noninvasive disease being curative in the majority of patients with 5- and 10-year actuarial survival rates of 75% and 60% reported.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Mucins / biosynthesis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002842.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 19
  •  go-up   go-down


26. Meshikhes AW, Al-Abkari HA, Al-Momen SA, Saad FE: Pseudomyxoma peritonei. Saudi Med J; 2006 Mar;27(3):389-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei.
  • Pseudomyxoma peritonei is very rare, and its exact pathogenesis is unknown.
  • It is characterized by intra-abdominal extracellular gelatinous fluid collections.
  • We report a case of pseudomyxoma peritonei in a 38-year-old Saudi male who presented with right iliac fossa mass and weight loss.
  • He was treated initially as an appendicular mass and computed tomography was helpful in making the diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Intestinal Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532086.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


27. Vullierme MP, Lévy P: [Diagnosis and follow-up of small intraductal papillary mucinous neoplasm of the pancreas]. Gastroenterol Clin Biol; 2009 Oct;33(10-11 Suppl):F88-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and follow-up of small intraductal papillary mucinous neoplasm of the pancreas].
  • Intraductal papillary mucinous tumours are diagnosed more and more often fortuitously.
  • The communication between the cystic lesion and the ductal system is essential for diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Neoplasms, Second Primary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Magnetic Resonance. Diagnosis, Differential. Follow-Up Studies. Humans. Practice Guidelines as Topic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758777.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Dodiuk-Gad R, Ziv M, Loven D, Schafer J, Shani-Adir A, Dyachenko P, Rozenman D: Sister Mary Joseph's nodule as a presenting sign of internal malignancy. Skinmed; 2006 Sep-Oct;5(5):256-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A skin biopsy from the nodule showed mucinous adenocarcinoma.
  • These results were consistent with a Sister Mary Joseph's nodule and led to the diagnosis of an occult colon carcinoma.
  • The patient had no risk factors for colorectal carcinoma.
  • The patient underwent surgery in another hospital, and died 3 months after the initial diagnosis of Sister Mary Joseph's nodule.
  • Stainings for mucin and for CK7 were positive, while staining for CK20 was negative.
  • The patient had no personal or family history of any malignancy or any risk factors for developing a carcinoma.
  • The patient was scheduled for a palliative resection of the umbilical nodule, combined with a laparoscopic inspection in search of the undetected primary tumor.
  • She died 4 months after the initial diagnosis of umbilical metastasis.
  • The mass was removed and diagnosed as a poorly differentiated adenocarcinoma, staining positively for carcinoembryonic antigen, and negatively for CK20, CK7, prostate-specific antigen, and prostatic acid phosphatase.
  • Both gastroscopy and colonoscopy failed to detect the primary tumor.
  • On bronchoscopy, it was found to be an invasive adenocarcinoma, consistent with a primary tumor of the lung.
  • Following demonstration of intra-abdominal spread of disease by CT scan, a second line chemotherapy was instituted with paclitaxel.
  • The patient died 3 weeks later, 9 months after the diagnosis of adenocarcinoma of the lung.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957443.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G: Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res; 2005 Dec 1;11(23):8332-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Two hundred and fifty-six tumors were MSI-H (20.3%): these were more frequently at a less advanced stage, right-sided, poorly differentiated, with mucinous phenotype, and expansive growth pattern than microsatellite stable carcinomas.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Antimetabolites, Antineoplastic / therapeutic use. Carrier Proteins / genetics. DNA-Binding Proteins / genetics. Female. Fluorouracil / therapeutic use. Humans. Male. MutS Homolog 2 Protein / genetics. Neoplasm Staging. Nuclear Proteins / genetics. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jun 15;12(12):3866-7; author reply 3867 [16778117.001]
  • [ErratumIn] Clin Cancer Res. 2006 Jun 15;12(12):3868-9
  • (PMID = 16322293.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antimetabolites, Antineoplastic; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Sanada Y, Yoshida K: A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes. J Gastrointestin Liver Dis; 2008 Dec;17(4):457-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes.
  • Here we report a case of benign intraductal papillary-mucinous neoplasm (IPMN) of the pancreas containing two major subtypes.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Mixed Tumor, Malignant / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Cholangiopancreatography, Endoscopic Retrograde. Humans. Male. Mucin-2 / metabolism. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastrointestin Liver Dis. 2009 Jun;18(2):251-2 [19565062.001]
  • (PMID = 19104710.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Mucin-2
  •  go-up   go-down


31. Goh BK, Ooi LL, Kumarasinghe MP, Tan YM, Cheow PC, Chow PK, Chung YF, Wong WK: Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology; 2006;6(6):520-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm.
  • RESULTS: There were 10 patients with a median age of 62 years (range 40-73).
  • Seven of the PENs were classified as benign, 2 were potentially malignant, and 1 was frankly malignant with lymph node involvement.
  • Five of these neoplasms were benign, 2 were borderline and 3 were malignant (1 carcinoma in situ).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel and IAP.
  • (PMID = 17124434.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


32. Bharti KH, Lodha ND, Wald MS: Mucinous eccrine carcinoma of lower eyelid: a case report. Indian J Pathol Microbiol; 2007 Oct;50(4):764-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous eccrine carcinoma of lower eyelid: a case report.
  • A rare case of primary mucinous eccrine carcinoma of the lower eyelid in a 45 year old female is described.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Eccrine Glands / pathology. Eyelid Neoplasms / diagnosis. Eyelid Neoplasms / pathology
  • [MeSH-minor] Eyelids / pathology. Female. Humans. Melanoma / diagnosis. Middle Aged

  • Genetic Alliance. consumer health - Eccrine Mucinous Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306545.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


33. Lee HY, Lee KS, Han J, Kim BT, Cho YS, Shim YM, Kim J: Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer; 2009 Aug;65(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons.
  • We aimed to evaluate the CT, PET, and pathologic findings of solitary pulmonary nodular mucinous and nonmucinous bronchioloalveolar carcinomas (BACs).
  • From August 2003 to March 2008, we saw 24 patients with solitary pulmonary nodular mucinous (n=6) or nonmucinous (n=18) BACs that were resected.
  • CT and PET findings of the lesions were assessed in terms of size, solidity, morphologic characteristics, attenuation and maximum standardized uptake value (mSUV).
  • All nonmucinous BACs appeared as a pure ground-glass opacity (GGO) nodule, whereas mucinous BACs appeared as solid (n=4) or part-solid (n=2) nodules.
  • CT attenuation values were significantly higher for mucinous BACs (-21.0 HU+/-4.9) than for nonmucinous BACs (-491.8 HU+/-172.5) (P<.001).
  • Mean mSUVs were 2.3+/-1.9 for mucinous BACs and 0.5+/-0.8 for nonmucinous BACs (P=.007), but mSUVs were not statistically different after size adjustment (r=0.371, P=.081).
  • Mucinous BACs appear as solid or part-solid nodules at CT, whereas nonmucinous BACs present as pure GGO nodules.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Mucinous / pathology. Lung Neoplasms / pathology. Positron-Emission Tomography. Solitary Pulmonary Nodule / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111932.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


34. Morand C, Verrièle V, Valo I, Remoue P, Paillocher N, Chassevent A: Pure mucinous carcinomas of the breast: prognostic study including DNA flow cytometry. Cytometry B Clin Cytom; 2009 Jan;76(1):56-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure mucinous carcinomas of the breast: prognostic study including DNA flow cytometry.
  • BACKGROUND: Prognostic factors for pure mucinous carcinomas of the breast are controversial; data on DNA ploidy and S-phase fraction (SPF) are lacking.
  • METHODS: DNA flow cytometry was performed on 69 fresh or frozen pure mucinous carcinomas samples.
  • These two parameters were of prognostic value respectively for disease-free (P=0.035) and overall survival (0.050).
  • Disease-free and overall survivals were not influenced by nodal status and hormone receptors (HRs) status.
  • Patients with aneuploid tumors had shorter disease-free survival than patients with diploid tumors (P=0.031).
  • CONCLUSION: We identified a subset of patients with a poor prognosis, namely those with large aneuploid tumors.
  • This study confirms the good prognosis of pure mucinous carcinomas, particularly when tumor is less than 2 cm (corresponding to cases without lymph nodes involvement), thus challenging the need for axillary nodal examination.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. DNA / genetics
  • [MeSH-minor] Adult. Aged. Aneuploidy. Disease-Free Survival. Female. Flow Cytometry. Humans. Kaplan-Meier Estimate. Middle Aged. Prognosis. Tumor Burden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Clinical Cytometry Society.
  • (PMID = 18642325.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


35. Scott M, McCluggage WG: Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol Histopathol; 2006 01;21(1):81-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian carcinoma is the most lethal gynaecological malignancy, most tumours being advanced at presentation.
  • It is stressed that ovarian carcinoma is a heterogeneous group of neoplasms with several different morphological types, each with their own underlying molecular genetic events.
  • Recent data suggest that mucinous ovarian cancers and a small subset of serous cancers (low grade ovarian serous carcinoma) develop through a well-defined adenoma-carcinoma sequence while the much more common high grade ovarian serous carcinoma develops de novo from the ovarian surface epithelium or the epithelium of cortical inclusion cysts.
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antineoplastic Protocols. Epithelium / pathology. Female. Humans. Mutation. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267789.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 93
  •  go-up   go-down


36. Ma XL, Sun HJ, Wang YS, Huang SH, Xie JW, Zhang HW: Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma. World J Gastroenterol; 2006 Jul 7;12(25):3965-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma.
  • AIM: To study the expression of Sonic hedgehog pathway-related molecules, Sonic hedgehog (Shh) and Gli1 in gastric carcinoma.
  • METHODS: Expression of Shh in 56 gastric specimens including non-cancerous gastric tissues, gastric adenocarcinoma, gastric squamous cell carcinoma was detected by RT-PCR, in situ hybridization and immunohistochemistry.
  • RESULTS: The positive rate of Shh and Gli1 expression was 0.0%, 0.0% in non-cancerous gastric tissues while it was 66.7%, 57.8% respectively in gastric adenocarcinoma, and 100%, 100% respectively in gastric squamous cell carcinoma.
  • There was a significant difference between the non-cancerous gastric tissues and gastric carcinoma (P<0.05).
  • Elevated expression of Shh and Gli1 in gastric tubular adenocarcinoma was associated with poorly differentiated tumors while the expression was absent in gastric mucinous adenocarcinoma.
  • CONCLUSION: The elevated expression of Shh and Gli1 in gastric adenocarcinoma and gastric squamous cell carcinoma shows the involvement of activated Shh signaling in the cellular proliferation of gastric carcinogenesis.
  • It suggests Shh signaling gene may be a new and good target gene for gastric tumor diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jun;127(12):2763-72 [10821773.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):99-104 [16112412.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):172-80 [11175816.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Neurosci. 2002 Feb;5(2):103-10 [11788837.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):58-61 [9731532.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9055-67 [11074003.001]
  • (PMID = 16810741.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC4087703
  •  go-up   go-down


37. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
  • Distinction of primary ovarian epithelial tumors from metastatic adenocarcinomas is challenging for tumors exhibiting mucinous, endometrioid, or mixed endometrioid/mucinous differentiation.
  • Metastatic carcinomas with these types of differentiation can be derived from several sites, including the gastrointestinal tract and the uterus.
  • Most endocervical adenocarcinomas exhibit mucinous and/or endometrioid differentiation; they infrequently metastasize to the ovaries but may simulate primary ovarian tumors [both atypical proliferative (borderline) and carcinoma].
  • The performance of this expression pattern for identifying metastatic endocervical adenocarcinomas in the ovaries among primary ovarian tumors and other metastatic adenocarcinomas having mucinous and/or endometrioid/endometrioidlike differentiation has not been evaluated.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • The HPV status of the endocervical adenocarcinomas was determined by in situ hybridization and polymerase chain reaction (when in situ hybridization was negative).
  • Mean and median expression values for HPV-positive endocervical adenocarcinomas (99%, 100%; range 90% to 100%) were substantially higher than those for primary ovarian mucinous (5%, 0%; range 0% to 70%) and endometrioid (20%, 10%; range 0% to 100%) tumors, HPV-unrelated endocervical adenocarcinomas (0%, 0%; range 0% to 60%), metastatic adenocarcinomas of unknown origin (11%, 0%; range 0% to 30%), and adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin (40%, 35%; range 0% to 90%); only the 15 HPV-positive endocervical adenocarcinomas and 6 other tumors had values of 80% or greater.
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction


38. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Jarle Christensen I, Gayther S, Jacobs IJ, Høgdall CK: Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study. Pathology; 2008 Aug;40(5):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To determine the variation in expression of carcinoembryonic antigen (CEA) in 760 epithelial ovarian tumours from Denmark, and to correlate expression with clinicopathological parameters and prognosis for the disease.
  • METHODS: Using tissue arrays (TA), we analysed CEA expression in tissues from 189 women diagnosed with low malignant potential ovarian tumours (LMP, borderline ovarian tumours) and 571 women diagnosed with ovarian cancer (OC).
  • A higher proportion of mucinous tumours were positive compared with other histological subtypes (p<0.00001).
  • A univariate survival analysis suggested a shorter disease specific survival for patients with 30% or higher CEA expression in the tumour tissue (p = 0.004).
  • FIGO stage, residual tumour after primary surgery, age at diagnosis, other histological types versus serous adenocarcinoma and low versus high histological grade tumours were also prognostic factors.
  • CONCLUSION: These data suggest that CEA expression is an independent prognostic factor for mucinous OC in Danish patients.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604735.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 61107
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


39. Tsuchiya T, Nakahama K, Asakawa Y, Maemura T, Tanaka M, Takeda S, Morita M, Morita I: The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor. Gynecol Endocrinol; 2009 Feb;25(2):104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissues with the highest expression levels of VEGF (VEGF-H) were malignant tumors.
  • The VEGF expression levels in some malignant tumors (VEGF-L) were as low as that in benign tumors.
  • The PEDF expression levels in VEGF-L malignant tumors were significantly lower than those in benign tumors.
  • On the other hand, the PEDF expression levels in VEGF-H malignant tumor tissues were not significantly different from those in benign tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / physiopathology. Eye Proteins / genetics. Nerve Growth Factors / genetics. Ovarian Neoplasms / pathology. Ovarian Neoplasms / physiopathology. Serpins / genetics. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood supply. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / physiopathology. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Endometrioid / blood supply. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / physiopathology. Female. Gene Expression Regulation, Neoplastic. Humans. Microcirculation / physiology. Neoplasms / blood supply. Neoplasms / pathology. Neoplasms / physiopathology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253105.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Eye Proteins; 0 / Nerve Growth Factors; 0 / Serpins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / pigment epithelium-derived factor
  •  go-up   go-down


40. Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M: Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer; 2006 May-Jun;16(3):986-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients' demographics together with disease characteristics, treatment-related variables, and outcomes were recorded.
  • Cox proportional hazard models were built to model time to progression using predictor variables such as age, cancer stage, tumor grade, residual disease, percentage change in CA125 level from baseline, and degree of necrosis in resected tumor specimens.
  • Cox regressions revealed three significant predictive variables of time to first progression: younger age (hazard ratio [HR] = 0.95, 95% CI 0.92-0.98, P= 0.004), residual disease (P= 0.048), and the absence/minimal tumor necrosis after three cycles of neoadjuvant chemotherapy (HR = 1.97, 95% CI 1.01-3.87, P= 0.048).
  • The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Aged. Antineoplastic Combined Chemotherapy Protocols. Area Under Curve. CA-125 Antigen / analysis. Carboplatin / therapeutic use. Carcinoma / diagnosis. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Disease-Free Survival. Endometrial Neoplasms / diagnosis. Female. Humans. Necrosis. Ovariectomy / statistics & numerical data. Paclitaxel / therapeutic use. Prognosis. Retrospective Studies. Second-Look Surgery / methods. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803473.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


41. Cho LC, Hsu YH: Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. Kaohsiung J Med Sci; 2008 May;24(5):227-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast.
  • Androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) expression characteristics were evaluated using immunohistochemistry stain, comparing patient age, tumor size and axillary lymph node status for 23 pure mucinous and 105 non-mucinous infiltrating ductal carcinomas in the human female breast.
  • Mucinous carcinoma with axillary lymph node metastasis occurred less frequently than non-mucinous carcinoma (11.8% vs. 55.2%; p = 0.01).
  • Compared with the non-mucinous type, mucinous carcinoma specimens showed less AR expression (21.7% vs. 51.4%; p = 0.01) but more ER expression (78.3% vs. 52.4%; p = 0.02).
  • In addition, AR expression was also associated with ER and/or PR coexpression (37/74, 50%) in infiltrating ductal carcinoma.
  • But only three of 20 (15%) mucinous carcinoma specimens with AR expression had associated ER and/or PR coexpression.
  • Our findings revealed that mucinous carcinoma samples from the breast show distinct clinicopathologic and hormone receptor expression features compared to non-mucinous carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Breast Neoplasms / chemistry. Receptors, Androgen / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508419.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


42. Leiman G: My approach to pancreatic fine needle aspiration. J Clin Pathol; 2007 Jan;60(1):43-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article focuses attention on specimen handling, with particular reference to rapid on-site evaluation.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Humans. Patient Selection

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] Acta Cytol. 1983 Sep-Oct;27(5):500-4 [6578648.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Diagn Cytopathol. 1985 Apr-Jun;1(2):105-10 [3836074.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):69-71 [3720483.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):72-5 [3522134.001]
  • [Cites] Acta Cytol. 1986 Jul-Aug;30(4):430-4 [3461652.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):39-42 [3336955.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):43-8 [2447722.001]
  • [Cites] Acta Cytol. 1988 Jul-Aug;32(4):447-51 [3400383.001]
  • [Cites] Acta Cytol. 1992 Sep-Oct;36(5):655-60 [1523921.001]
  • [Cites] Acta Cytol. 1992 Nov-Dec;36(6):881-6 [1449026.001]
  • [Cites] Am J Clin Pathol. 1992 Nov;98(5):478-88 [1283055.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):889-93 [8249508.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):908-12 [8249512.001]
  • [Cites] AJR Am J Roentgenol. 1988 Sep;151(3):493-4 [3261508.001]
  • [Cites] Acta Radiol. 1988 Sep-Oct;29(5):535-9 [3048349.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):37-45 [8807250.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):396-410 [8834314.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):975-9 [8842177.001]
  • [Cites] Diagn Cytopathol. 1997 Feb;16(2):112-6 [9067100.001]
  • [Cites] Am Surg. 1997 Aug;63(8):675-9; discussion 679-80 [9247432.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1329-33 [9707060.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):423-7 [9839131.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3 [10367874.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):1111-5 [10425311.001]
  • [Cites] Diagn Cytopathol. 2005 Feb;32(2):65-9 [15637684.001]
  • [Cites] Diagn Cytopathol. 2005 Apr;32(4):204-10 [15754366.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):697-707 [16203289.001]
  • [Cites] Gut. 2000 Feb;46(2):244-9 [10644320.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2255-60 [11007226.001]
  • [Cites] Diagn Cytopathol. 1988;4(4):316-22 [3254809.001]
  • [Cites] Diagn Cytopathol. 1989;5(3):263-8 [2551616.001]
  • [Cites] Acta Cytol. 1989 Nov-Dec;33(6):936-9 [2686327.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):388-91 [2612315.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):408-11 [2612319.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):142-9 [2164767.001]
  • [Cites] Radiology. 1991 Jan;178(1):253-8 [1984314.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):26-9; discussion 29-30 [1824810.001]
  • [Cites] Am J Clin Pathol. 1994 Apr;101(4):483-7 [8160642.001]
  • [Cites] Aust N Z J Surg. 1994 Jun;64(6):444-6 [7912067.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):1-10 [7846994.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):23-7 [7847005.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1230-5 [7535275.001]
  • [Cites] Acta Cytol. 1995 May-Jun;39(3):485-8 [7762337.001]
  • [Cites] Diagn Cytopathol. 1995 Mar;12(2):113-9 [7774489.001]
  • [Cites] Diagn Cytopathol. 1990;6(5):336-40 [1705496.001]
  • [Cites] Surg Gynecol Obstet. 1991 Sep;173(3):193-7 [1925879.001]
  • [Cites] Acta Cytol. 1991 Sep-Oct;35(5):546-8 [1927196.001]
  • [Cites] Diagn Cytopathol. 1991;7(4):341-5 [1935510.001]
  • [Cites] Diagn Cytopathol. 1992;8(1):65-7 [1551367.001]
  • [Cites] Acta Cytol. 1992 Jul-Aug;36(4):471-6 [1636336.001]
  • [Cites] Surgery. 1995 Sep;118(3):472-8 [7652681.001]
  • [Cites] Diagn Cytopathol. 1995 Aug;13(2):120-3 [8542789.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):233-46 [8575283.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):182-90 [8629395.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):470-4 [11275888.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Endoscopy. 2001 Oct;33(10):824-31 [11571676.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):106-12 [12004358.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):291-6 [12145615.001]
  • [Cites] Cancer. 2002 Aug 25;96(4):232-9 [12209665.001]
  • [Cites] Acta Cytol. 2002 Sep-Oct;46(5):813-8 [12365212.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):325-34 [12451561.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):362-9 [12478684.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8 [12559193.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):44-50 [12589645.001]
  • [Cites] Surgery. 2003 May;133(5):459-63 [12773972.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):341-8 [12789912.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):657-62 [12920762.001]
  • [Cites] Am J Clin Pathol. 2003 Sep;120(3):398-404 [14502804.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):723-6 [14526668.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):733-8 [14526670.001]
  • (PMID = 16698956.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 89
  • [Other-IDs] NLM/ PMC1860594
  •  go-up   go-down


43. Sugai M, Umezu H, Yamamoto T, Jiang S, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M: Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors. Pathol Int; 2008 Nov;58(11):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors.
  • Ovarian mucinous adenoma, mucinous tumors of borderline malignancy, and mucinous adenocarcinoma had positive nuclear staining for HNF4 alpha (41/45, 91%).
  • One-third (34%) of mucinous tumors had P1-positive staining and most had P1/P2-positive staining (93%).
  • MUC2- and MUC5AC-positive staining was observed in 34% and 95% of mucinous tumors, respectively.
  • The histological subtype of these mucinous tumors was not correlated with HNF4 alpha expression.
  • On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.
  • Thus, HNF4 alpha is demonstrated to be a useful marker for histological and cytological diagnosis of ovarian mucinous tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenoma, Mucinous / metabolism. Hepatocyte Nuclear Factor 4 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ascitic Fluid / metabolism. Ascitic Fluid / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Mucin 5AC. Mucin-2. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844932.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 4; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


44. Ilker S, Ali F, Yavuz K: Education and imaging. Gastrointestinal: drain-site recurrence after resection of colon cancer. J Gastroenterol Hepatol; 2008 Sep;23(9):1459
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education and imaging. Gastrointestinal: drain-site recurrence after resection of colon cancer.
  • [MeSH-major] Abdominal Neoplasms / surgery. Adenocarcinoma, Mucinous / surgery. Colectomy. Colonic Neoplasms / surgery. Drainage. Hepatectomy. Liver Neoplasms / surgery. Neoplasm Seeding. Wound Healing

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854001.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


45. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM: Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res; 2006 Jan 15;66(2):828-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accumulating evidence suggests that intestinal microbial organisms may play an important role in triggering and sustaining inflammation in individuals afflicted with inflammatory bowel disease (IBD).
  • Using real-time PCR, we found that Helicobacter organisms concentrate in the cecum, the preferred site of tumor development.
  • Mucinous adenocarcinomas develop 5 to 30 weeks after infection and are preceded by an early inflammatory phase, consisting of increased proliferation of epithelial cells; increased numbers of cyclooxygenase-2-positive cells, CD4(+) T cells, macrophages; and increased MHC class II expression.
  • [MeSH-minor] Animals. Cecum / microbiology. Cell Proliferation. Cytokines / biosynthesis. DNA, Bacterial / analysis. Female. Genetic Predisposition to Disease. Inflammation. Male. Mice. Polymerase Chain Reaction. Proto-Oncogene Proteins c-myc. Risk Factors. Signal Transduction. Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / physiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - 129-Smad3<tm1Par>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2002 Jan 15;168(2):900-8 [11777988.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3998-4004 [15899788.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1793-806 [15920164.001]
  • [Cites] Cancer Cell. 2005 May;7(5):403-5 [15894259.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6042-50 [14522933.001]
  • [Cites] Keio J Med. 2002 Dec;51 Suppl 2:63-8 [12528941.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Sep;279(3):G492-9 [10960347.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G764-78 [11518689.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):217-20 [15655344.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):962-8 [14871826.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27 [15000146.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):807-21 [14557817.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S56-61 [15508104.001]
  • [Cites] J Infect Dis. 2001 Jul 15;184(2):227-30 [11424022.001]
  • [Cites] Lab Anim. 1981 Jan;15(1):57-9 [7022018.001]
  • [Cites] BMC Cell Biol. 2002 Jun 21;3:15 [12097147.001]
  • [Cites] Adv Exp Med Biol. 2001;490:21-32 [11505971.001]
  • [Cites] Immunity. 2004 Oct;21(4):491-501 [15485627.001]
  • [Cites] Immunol Rev. 2005 Apr;204:184-94 [15790359.001]
  • [Cites] Carcinogenesis. 1997 Jan;18(1):233-6 [9054612.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1061-7 [15809351.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):691-702 [12547727.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1346-54 [11984521.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:115-27 [11966532.001]
  • [Cites] Clin Ter. 2004 May;155(5):187-99 [15344567.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9 [7777546.001]
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):31-8 [10766420.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] Infect Immun. 1996 May;64(5):1548-58 [8613359.001]
  • [Cites] Nat Immunol. 2005 Jun;6(6):600-7 [15852008.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] Cancer Cell. 2005 May;7(5):411-23 [15894262.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):971-8 [12847269.001]
  • [Cites] Immunogenetics. 2000 Aug;51(10):869-72 [10970103.001]
  • [Cites] APMIS. 2004 Jan;112(1):49-56 [14961975.001]
  • [Cites] Cancer Res. 1975 Feb;35(2):287-90 [162868.001]
  • [Cites] In Vivo. 1996 May-Jun;10(3):285-92 [8797029.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):737-46 [15753207.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13180-5 [10557294.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2495-504 [10082515.001]
  • [Cites] Virchows Arch. 1995;425(6):617-29 [7535166.001]
  • [Cites] Gut. 2001 Jun;48(6):743-7 [11358884.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1280-91 [10064594.001]
  • [Cites] Fukushima J Med Sci. 2001 Jun;47(1):1-11 [11764413.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):739-51 [11839595.001]
  • [Cites] EMBO J. 2002 Sep 16;21(18):4820-30 [12234922.001]
  • [Cites] Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S39-47 [10772417.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6362-6 [12438215.001]
  • [Cites] J Surg Oncol. 2002 Aug;80(4):204-13 [12210035.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G315-9 [15246966.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2253-7 [12057927.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G361-6 [14766534.001]
  • (PMID = 16424015.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI053568; United States / NCI NIH HHS / CA / R01 CA068328; United States / NIAID NIH HHS / AI / 1R01 AI 053568-01; United States / NCI NIH HHS / CA / 2R01 CA 68328
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA, Bacterial; 0 / Proto-Oncogene Proteins c-myc; 0 / Smad3 Protein; 0 / Smad3 protein, mouse; 0 / Transforming Growth Factor beta
  •  go-up   go-down


46. Chaleoykitti B: Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital. J Med Assoc Thai; 2006 Jan;89(1):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital.
  • OBJECTIVE: The objective of the present study was to compare the clinicopathological significance between mucinous carcinoma and nonmucinous adenocarcinoma.
  • MATERIAL AND METHOD: Patients with carcinoma of the colon and rectum who had the first operation in the Department of Surgery, Phramongkutklao Hospital between 1999 and 2004 were included in the present study.
  • Patients were divided into two groups: nonmucinous group and mucinous group.
  • Forty four (10.7%) were mucinous carcinoma.
  • CONCLUSION: Colorectal mucinous carcinoma had no clinicopathological difference from nonmucinous adenocarcinoma of colon and rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583577.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


47. Belcher E, Nicholson AG, Hansell DM, Goldstraw P: Imaging characteristics of a mucinous colorectal pulmonary metastasis. Ann Thorac Surg; 2008 Nov;86(5):1698
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of a mucinous colorectal pulmonary metastasis.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19049786.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


48. Rafii A, Ferron G, Lacroix-Triki M, Dalenc F, Gladieff L, Querleu D: Abdominal wall metastasis of ovarian carcinoma after low transverse abdominal incision: report of two cases and review of literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal wall metastasis of ovarian carcinoma after low transverse abdominal incision: report of two cases and review of literature.
  • Occurrence of parietal metastases after surgery for a suspect adnexal mass may worsen the prognosis of the disease.
  • We report two cases with development of parietal dissemination of ovarian carcinomas after Pfannenstiel incision.
  • The parietal extension of the disease may need major parietal resection that can worsen the functional and general outcome of the patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Granulosa Cell Tumor / secondary. Neoplasm Seeding. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515617.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; BEP protocol
  •  go-up   go-down


49. Yousem SA: Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Mod Pathol; 2005 Jun;18(6):816-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study.
  • Six cases of an unusual variant of primary pulmonary adenocarcinoma resembling colorectal and sinonasal adenocarcinoma are presented.
  • Pulmonary intestinal-type adenocarcinoma occurs in elderly Caucasians and is associated with a histology characteristic of colorectal/enteric adenocarcinoma: a garland-like architecture with a 'gland in gland' periphery, central 'dirty' necrosis, and elongated stratified columnar cells, lacking significant goblet or signet ring differentiation.
  • While a resemblance to intestinal adenocarcinoma by light microscopy is present, immunohistochemical studies comparing these carcinomas with metastatic colorectal adenocarcinoma clearly show a respiratory phenotype with the neoplastic cells expressing thyroid transcription factor-1 and cytokeratin 7 to the exclusion of cytokeratin 20, and failing to express CDX-2.
  • The differential diagnosis with other pulmonary adenocarcinomas, especially those with mucinous differentiation, is discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Keratin-7. Keratins / analysis. Male. Middle Aged. Mucin 5AC. Mucin-1 / analysis. Mucin-2. Mucins / analysis. Nuclear Proteins / analysis. Trans-Activators / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605076.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 156560-97-3 / Cdx-2-3 protein; 68238-35-7 / Keratins
  •  go-up   go-down


50. Watanabe Y, Horiuchi A, Sato K, Yukumi S, Sugishita H, Yoshida M, Doi T, Yamamoto Y, Ishida N, Kameoka K, Kawachi K: Metachronous intraductal papillary mucinous neoplasm with carcinoma in situ of the pancreas arising within a short interval: report of a case. Surg Today; 2010 May;40(5):465-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous intraductal papillary mucinous neoplasm with carcinoma in situ of the pancreas arising within a short interval: report of a case.
  • A 61-year-old man with an intraductal papillary mucinous neoplasm (IPMN) and carcinoma in situ (CIS) of the pancreatic body initially underwent a distal pancreatectomy.
  • Intraductal papillary mucinous neoplasm of the pancreatic head was diagnosed 17 months later using peroral pancreatoscopy (POPS) including a biopsy, revealing IPMN with highly dysplastic changes.
  • In addition, endoscopic US, endoscopic retrograde cholangiopancreatography, intraductal US, or POPS should be included in pathological examinations to avoid missing opportunities to treat lesions such as noninvasive IPMN with a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma in Situ / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Surgery. 2000 May;127(5):536-44 [10819062.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):576-89 [7726368.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Am J Surg. 1999 Feb;177(2):117-20 [10204552.001]
  • [Cites] Am Surg. 2001 May;67(5):400-6 [11379635.001]
  • [Cites] Surg Today. 2008;38(4):371-6 [18368332.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • (PMID = 20425552.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Mizumoto M, Honjo G, Kobashi Y, Nishimura S, Nakamura Y, Yoshimura T, Awane M, Kato Y, Furuyama H, Asao Y, Maeda H, Takakuwa H, Matsusue S: Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the pancreas, especially in relation to dysplastic epithelial changes. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):704-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the pancreas, especially in relation to dysplastic epithelial changes.
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasms have a better prognosis than ductal adenocarcinomas of the pancreas.
  • The aim of this study was to evaluate the malignant potential of IPMNs by their preoperative images.
  • METHODOLOGY: Forty-three intraductal papillary mucinous neoplasms were divided into 3 duct ectatic types using preoperative images (the main duct type, the branch duct type, and the mixed type), and into 2 groups using resected specimens (the malignant group including severe dysplasia based on the WHO classification and the benign group).
  • RESULTS: Two thirds of main duct type cases were in the malignant group.
  • For the branch duct and mixed types, the diameters of the tumor and detectable mural nodules were larger in the malignant group than in the benign group.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613438.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


52. Ataseven H, Yüksel I, Arhan M, Köklü S, Başar O, Ertuğrul I, Saşmaz N: Mucinous carcinoma of the rectum in a boy presenting with bloody diarrhea. Clin Colorectal Cancer; 2009 Jul;8(3):169-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the rectum in a boy presenting with bloody diarrhea.
  • Colorectal carcinoma, primarily a disease of adulthood, accounts for 0.2% of malignancies in adolescents and has very rarely been reported in childhood.
  • Histologic examination revealed a mucinous rectal adenocarcinoma.
  • He died 4 months after diagnosis.
  • This case highlights the need for awareness of colorectal carcinomas and their invasive nature in the differential diagnosis of rectal bleeding and diarrhea in adolescents.
  • [MeSH-major] Abdominal Pain / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Diarrhea / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Fatal Outcome. Gastrointestinal Hemorrhage / diagnosis. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632933.001).
  • [ISSN] 1938-0674
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Bosch Roig CE, Roselló-Sastre E, Alonso Hernández S, Almenar Cubells D, Grau Cardona E, Camarasa Lillo N, Bautista D, Molins Palau C: Prognostic value of the detection of lymph node micrometastases in colon cancer. Clin Transl Oncol; 2008 Sep;10(9):572-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION AND OBJECTIVES: A study is made of the clinical repercussions of occult metastases-micrometastases (MMs+)-or isolated tumour cells (ITCs+) in the lymph nodes of patients with stage IIA and IIB colon adenocarcinoma initially considered as corresponding to N0.
  • MATERIAL AND METHODS: A retrospective study of 39 patients with stage IIA and IIB (T3-T4 N0 M0) colon adenocarcinoma, subjected to similar surgical and adjuvant chemotherapy treatment, with long and careful follow-up (minimum: 5 years, mean: 81.7 months) was performed on their previously resected lymph nodes, with the aid of new histological and immunohistochemical (cytokeratin) sections, in order to detect MMs or ITCs.
  • Disease-free survival (DFS) and global survival (GS) in the two groups (patients with MMs+ or ITCs+ vs. patients without MMs or ITCs) were compared at 5 years based on the corresponding Kaplan-Meier survival curves, with the Breslow test.
  • GS of the whole series at 5 years was 89.74% (35 patients alive) with a DFS at 5 years of 79.49% (31 patients free of disease), but the 2 cases with MMs+ were dead at 5 years, with high statistical differences between both groups (MMs+/MMs-) (p<0.0001).
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Colonic Neoplasms / blood. Colonic Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4232-41 [12377967.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2740-1 [14669301.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] J Surg Oncol. 2004 Mar;85(3):166-70 [14991889.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):402-6 [14976530.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):300-4 [11352302.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):917-20 [1717210.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):676-80 [17005470.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] Colorectal Dis. 2003 Mar;5(2):164-8 [12780907.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1244-9 [9788387.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):637-42 [8891622.001]
  • [Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1465-71 [9407986.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] Int J Colorectal Dis. 1998;13(2):99-102 [9638496.001]
  • (PMID = 18796374.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


54. Cao D, Ji H, Ronnett BM: Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol; 2005 Jan;24(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
  • Metastatic pancreatic mucinous adenocarcinomas in the ovaries can be difficult to distinguish from primary ovarian mucinous neoplasms because the former can simulate the latter grossly and histologically and both tumor types share the same cytokeratin 7/cytokeratin 20 immunoprofile.
  • We previously reported the utility of loss of Dpc4 expression in distinguishing metastatic pancreatic carcinomas from primary ovarian mucinous tumors.
  • Recently several new pancreatic carcinoma markers have been identified, including mesothelin, fascin, and prostate stem cell antigen (PSCA).
  • In this study we investigate the expression patterns of these markers in 35 primary ovarian mucinous tumors (28 atypical proliferative [borderline] tumors and 7 invasive carcinomas) and 11 metastatic pancreatic mucinous carcinomas in the ovary.
  • Primary ovarian mucinous tumors expressed mesothelin (17%), fascin (26%), and PSCA (43%) less frequently than metastatic pancreatic adenocarcinomas (73%, 73%, and 82%, respectively).
  • Expression of all three markers was seen only in metastatic pancreatic adenocarcinomas (45%), and coexpression of at least two markers was observed significantly more frequently in metastatic (82%) than primary ovarian mucinous tumors (17%).
  • Our results indicate that an immunohistochemical panel including Dpc4, mesothelin, fascin, and PSCA is useful for evaluating difficult mucinous tumors in the ovary when the differential diagnosis includes metastatic pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. Membrane Glycoproteins / metabolism. Microfilament Proteins / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm. Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Probability

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626919.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / mesothelin; 146808-54-0 / fascin
  •  go-up   go-down


55. Kuehn A, Paner GP, Skinnider BF, Cohen C, Datta MW, Young AN, Srigley JR, Amin MB: Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications. Am J Surg Pathol; 2007 Oct;31(10):1528-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromophobe renal cell carcinoma and renal oncocytoma are reported to be variably positive for Ksp-cad with some studies suggesting a discriminatory role for Ksp-cad.
  • Immunoreactivity in other tumors with granular eosinophilic cytoplasm including clear cell and papillary renal cell carcinomas needs to be clearly elucidated and its expression in emerging novel and other unusual renal epithelial neoplasm subtypes including tumors with uncertain histogenesis is not yet known.
  • Reactivity with Ksp-cad was observed in the following tumors: chromophobe renal cell carcinoma [23/25 (92%), diffuse (>50% of tumor cells)] positivity and membranous characteristically accentuating the "plant cell-like" histomorphology of the typical (clear) type, renal oncocytoma [15/20 (75%), usually diffuse staining with predominantly membranous accentuation], papillary renal cell carcinoma [5/17 (29%) all focal to moderate, eosinophilic type or type 2-3/7 (43%), basophilic type or type 1-2/10 (20%)], Xp11 translocation carcinoma [1/4 (25%), diffuse positivity] and clear cell renal cell carcinoma [6/36 (17%) all focal, clear cell renal cell carcinoma with prominent eosinophilic cells 1/7 (14%)].
  • Immunoreactivity was higher when evaluating whole histologic sections than with tissue microarrays for both chromophobe renal cell carcinoma (100% vs. 60%) and renal oncocytoma (100% vs. 55%).
  • No immunoreactivity was observed in mucinous tubular and spindle cell carcinomas (0/23), high-grade collecting duct carcinomas (of Bellini) (0/3), renal medullary carcinomas (0/2), and urothelial carcinomas (0/6).
  • The findings argue against the use of Ksp-cad in differentiating chromophobe renal cell carcinoma and renal oncocytomas and further support their relationship to the distal nephron.
  • Ksp-cad may be helpful in distinguishing these two tumor types from clear cell renal cell carcinoma with prominent eosinophilic cells particularly in cases with limited tissue samples (ie, needle core biopsy).
  • In the similar diagnostic setting, caution must be exercised, however, in differentiating chromophobe renal cell carcinoma and renal oncocytoma from the eosinophilic variant of papillary renal cell carcinoma as moderate expression of Ksp-cad may be observed in papillary renal cell carcinoma.
  • The histogenesis of mucinous tubular and spindle cell carcinoma remains debatable as this tumor does not express Ksp-cad, which is highly expressed normally in the thick ascending loop of Henle and the distal convoluted tubules.
  • In conclusion, Ksp-cad is a useful tumor type associated marker for distinguishing chromophobe renal cell carcinoma and renal oncocytoma from the wide range of nonintercalated cell-related adult renal epithelial neoplasms; addition of this marker to a panel comprised of other histologic subtype-associated markers may greatly facilitate histologic subclassification of adult renal epithelial neoplasms.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Kidney Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / pathology. Eosinophilia / metabolism. Eosinophilia / pathology. Humans. Immunoenzyme Techniques. Immunohistochemistry / methods. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895753.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH16 protein, human; 0 / Cadherins
  •  go-up   go-down


56. Onodera M, Nishigami T, Torii I, Sato A, Tao LH, Kataoka TR, Yoshikawa R, Tsujimura T: Comparison between colorectal low- and high-grade mucinous adenocarcinoma with MUC1 and MUC5AC. World J Gastrointest Oncol; 2009 Oct 15;1(1):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between colorectal low- and high-grade mucinous adenocarcinoma with MUC1 and MUC5AC.
  • AIM: To explore useful prognostic factors for mucinous adenocarcinoma (MAC) in the colon and rectum.
  • METHODS: MAC was divided into low- and high-grade types based on the degree of structural differentiation; low-grade MAC arisen from well to moderately differentiated adenocarcinoma and papillary carcinoma, and high-grade MAC from poorly differentiated adenocarcinoma and signet ring cell carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160777.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999097
  • [Keywords] NOTNLM ; Colon / MUC1 / MUC5AC / Mucinous adenocarcinoma / Rectum
  •  go-up   go-down


57. Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG: Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum; 2008 Jan;51(1):50-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medical records of 753 patients with primary colorectal cancer were retrospectively studied.
  • The outcome of patients with a component of signet-ring cells was compared to all patients with mucinous adenocarcinoma (defined as adenocarcinomas with > or = 50 percent mucin) to all patients with adenocarcinomas with a component of mucin (defined as adenocarcinomas with < 50 percent mucin) and to 100 randomly selected patients with adenocarcinomas lacking mucin or signet-ring cells.
  • RESULTS: Five percent of patients had a component of signet-ring cells, 3 percent had mucinous adenocarcinoma, 9 percent had a component of mucinous adenocarcinoma, and 83 percent had adenocarcinoma lacking mucinous or signet components.
  • Patients with a component of signet-ring cells and mucinous adenocarcinomas metastasized predominantly to the peritoneum/ovaries (75 and 56 percent of metastatic cases, respectively) and rarely to liver/lungs.
  • The pattern of metastases of patients with adenocarcinoma without mucinous or signet components predominantly involved the liver/lungs and rarely the peritoneum/ovaries (12.5 percent).
  • The pattern of metastases for patients with a component of mucinous adenocarcinoma was intermediate between mucinous adenocarcinoma and adenocarcinoma without mucin or signet-ring component.
  • CONCLUSIONS: Patients with a component of signet-ring cells cancers, similar to mucinous adenocarcinoma, have a predisposition to metastasize to the peritoneum/ovaries.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030531.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E: Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathol Res Pract; 2008;204(6):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
  • Few studies have compared maspin with VEGF in ovarian carcinoma.
  • Using immunohistochemistry, we examined maspin, VEGFA, VEGFC, and VEGFD expression in 60 ovarian carcinoma tissues (35 serous papillary carcinomas, 18 endometrioid carcinomas, and 7 primary ovarian mucinous carcinomas).
  • Maspin, VEGFC, and VEGFD are expressed in ovarian tumors with a poor prognostic parameters, and seem to play a role in ovarian cancer angiogenesis, progression, and lymph node metastases.
  • Our results indicate that in contrast to most other carcinomas, maspin expression is directly associated with the biological aggressiveness of ovarian carcinoma.
  • These results may offer new insights regarding the role of maspin in ovarian cancer and might also affect the diagnosis and treatment strategies.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Serpins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343598.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins; 0 / VEGFA protein, human; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


59. Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, Dubois A: Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol; 2008 May;15(5):1414-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
  • BACKGROUND AND AIMS: Pseudomyxoma peritonei (PMP) is characterized by peritoneal tumors arising from a perforated appendiceal adenoma or adenocarcinoma, but associated entry of enteric bacteria in the peritoneum has not been considered as a cofactor.
  • Because Gram-negative organisms can upregulate MUC2 mucin gene expression, we determined whether bacteria were detectable in PMP tissues.
  • METHODS: In situ hybridization was performed on resection specimens from five control subjects with noninflamed, nonperforated, non-neoplastic appendix and 16 patients with PMP [six with disseminated peritoneal adenomucinosis (DPAM) and 10 with peritoneal mucinous carcinomatosis (PMCA)].
  • Bacterial density and MUC2 expression were significantly (p < 0.05) higher in PMCA than in DPAM and controls and were highest in free mucin.
  • CONCLUSIONS: Multiple enteric bacteria are present in PMP, and bacterial density and MUC2 expression is highest in the malignant form of PMP.
  • Based on these observations, we propose that the bacteria observed in PMP may play a role in the mucinous ascites and perhaps promote carcinogenesis.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 1993 May;61(5):1799-809 [8478069.001]
  • [Cites] Lancet. 1992 Nov 14;340(8829):1194-5 [1359263.001]
  • [Cites] J Histochem Cytochem. 1995 Feb;43(2):115-23 [7529784.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Clin Infect Dis. 1996 Jul;23(1):101-6 [8816137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):967-72 [9023366.001]
  • [Cites] Mutat Res. 1997 Jun 13;391(1-2):79-86 [9219551.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1128-33 [9781653.001]
  • [Cites] Toxicon. 1999 May;37(5):815-23 [10219991.001]
  • [Cites] J Immunol. 1999 May 15;162(10):6233-7 [10229869.001]
  • [Cites] Ann Chir. 2005 Feb;130(2):63-9 [15737316.001]
  • [Cites] Lab Invest. 2005 May;85(5):702-15 [15765119.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Helicobacter. 2006 Feb;11(1):2-9 [16423084.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):86-90 [16427185.001]
  • [Cites] Inflamm Bowel Dis. 2006 Nov;12(11):1068-83 [17075348.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e110 [17121461.001]
  • [Cites] Gastroenterology. 2007 Feb;132(2):551-61 [17258726.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1009-23 [17383424.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5 [17481516.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 28;1406(3):251-9 [9630659.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):164-71 [11266521.001]
  • [Cites] J Radiol. 2001 Apr;82(4):463-8 [11353901.001]
  • [Cites] Surg Today. 2001;31(7):646-50 [11495161.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2253-7 [12057927.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):958-72 [12218214.001]
  • [Cites] Mol Pharmacol. 2002 Nov;62(5):1112-8 [12391274.001]
  • [Cites] J Obstet Gynaecol. 2002 Mar;22(2):223 [12521714.001]
  • [Cites] J Infect Dis. 2003 Apr 15;187(8):1165-77 [12695995.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Ann Intern Med. 2004 Apr 20;140(8):W33 [15096365.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17 [15194558.001]
  • [Cites] Acta Chir Scand. 1973;139(4):392-400 [4718184.001]
  • [Cites] J Histochem Cytochem. 1987 Sep;35(9):983-96 [3302022.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1636-40 [2208015.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • (PMID = 18299935.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082312-08; United States / NCI NIH HHS / CA / R01 CA082312; United States / NCI NIH HHS / CA / CA82312; United States / NCI NIH HHS / CA / R01 CA082312-08
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Probes; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins; 0 / RNA Probes
  • [Other-IDs] NLM/ NIHMS72052; NLM/ PMC2570966
  •  go-up   go-down


60. Salas-Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M, Santamaría S, Zamora JB: Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int; 2009 Dec;25(12):1073-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases.
  • BACKGROUND: Carcinoma of the colon and rectum is rare in the pediatric age group, and usually presents with an advanced stage disease bearing a poor prognosis.
  • Colorectal carcinoma should be considered in children with signs of intestinal obstruction, alteration in bowel habits, gastrointestinal bleeding and chronic abdominal pain.
  • METHODS: Between 1974 and 2007, 11 patients were identified and treated for colorectal carcinoma at the Oncology Unit.
  • The medical records were studied to analyze the age, sex, clinical presentation, diagnostic procedures, extent of disease (Dukes staging), treatment, histological types, and outcome.
  • Surgical procedures were done in 11 patients (incomplete resection with segmental resection in 4 patients, complete resection in the other 4, and biopsy alone in 3 patients).The predominant histological type was mucinous carcinoma.
  • CONCLUSIONS: Colorectal carcinoma in children is very uncommon and could be easily misdiagnosed, resulting in advanced stage disease at diagnosis.
  • Because radical surgery which is the mainstay of treatment is possible only in patients with early stage disease, a high level of awareness and early diagnosis are critical.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Antineoplastic Agents / therapeutic use. Colectomy / methods. Colonic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Biopsy. Chemotherapy, Adjuvant. Child. Colonoscopy. Costa Rica / epidemiology. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Prognosis. Retrospective Studies. Survival Rate / trends

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):39-41 [15654277.001]
  • [Cites] Cancer. 1958 Jul-Aug;11(4):855-7 [13561255.001]
  • [Cites] Surg Gynecol Obstet. 1962 Apr;114:438-42 [13898554.001]
  • [Cites] J Pediatr Surg. 1976 Dec;11(6):967-71 [1003308.001]
  • [Cites] Clin Genet. 1987 Jan;31(1):35-44 [3568432.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] Pediatrics. 1963 Oct;32:558-71 [14069097.001]
  • [Cites] J Chemother. 2002 Jun;14(3):301-8 [12120887.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1085-9; discussion 1089-90 [1403541.001]
  • [Cites] Eur J Pediatr Surg. 2003 Feb;13(1):66-8 [12664421.001]
  • [Cites] Dis Colon Rectum. 1976 Sep;19(6):529-34 [183939.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):952-5 [4016687.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1322-6 [3971300.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):919-21 [1640344.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1188-93 [8308690.001]
  • [Cites] Arch Surg. 1970 Apr;100(4):527-31 [4190476.001]
  • [Cites] Dis Colon Rectum. 1981 Jan-Feb;24(1):25-8 [7472098.001]
  • [Cites] Surgery. 1983 Mar;93(3):409-14 [6600855.001]
  • [Cites] Am J Surg. 1958 Jul;96(1):47-53 [13545485.001]
  • [Cites] Surg Gynecol Obstet. 1974 Feb;138(2):169-70 [4810853.001]
  • [Cites] Br J Surg. 1984 Apr;71(4):272-7 [6704677.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1560-2 [14605580.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2464-72 [200342.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):209-11 [17255833.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1189-91 [2553912.001]
  • [Cites] South Med J. 1976 Jan;69(1):24-7 [1246645.001]
  • (PMID = 19816697.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


61. Soto Delgado M, Pedrero Márquez G, Varo Solís C, Rodríguez-Rubio Cortadellas FO, Sánchez Bernal C, González Moreno D: [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma]. Actas Urol Esp; 2006 Feb;30(2):222-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma].
  • [Transliterated title] Adenocarcinoma mucinoso de uraco y pseudomixoma peritoneal.
  • The adenocarcinoma of the urachus is very rare tumor, with an incidence of 1/5.000.000 inhabitants, represents less than 0.001 of all types of bladder cancer.
  • Peritoneal pseudomixoma is a rare neoplasm characterized by mucinous acites that involvement the peritoneal surface and omentum.
  • Usually is associated with benign o malignant mucinous tumor of the appendix or ovary.
  • In this paper, we present a case of peritoneal pseudomixoma caused by a mucinous adenocarcinoma of the urachus.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Pseudomyxoma Peritonei / etiology. Urachus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700214.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB: Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg; 2005 Sep-Oct;9(7):922-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas.
  • The study goal was to analyze outcome after distal pancreatectomy for three subtypes of adenocarcinoma to determine the role of en bloc resection in surgical management.
  • A secondary aim was to identify those clinicopathologic factors correlating with survival in an analysis limited to ductal adenocarcinoma.
  • Medical records of consecutive patients undergoing distal pancreatectomy for adenocarcinoma between 1987 and 2003 were reviewed.
  • Clinicopathologic factors for patients undergoing distal pancreatectomy for ductal adenocarcinoma were subjected to both univariate and multivariate survival analyses.
  • Ninety-three patients underwent resection for ductal adenocarcinoma (66, 71%), mucinous cystadenocarcinoma (18, 19%), or adenocarcinoma associated with intraductal papillary mucinous neoplasm (IPMN) (9, 10%).
  • Median survival was 15.5 months, 30.2 months, and 50.7 months for ductal adenocarcinoma, mucinous cystadenocarcinoma, and adenocarcinoma associated with IPMN, respectively.
  • For ductal adenocarcinoma, tumor size greater than 3.5 cm, age greater than 60 years, and stage were factors that correlated with survival on a univariate analysis.
  • Four patients with ductal adenocarcinoma were actual 5-year survivors.
  • While en bloc resections are associated with a higher rate of complications, the majority are self-limited and mortality is low.
  • Long-term survival for patients with cystadenocarcinoma or IPMN-associated adenocarcinoma can be anticipated.
  • While rare, long-term survival for patients with ductal adenocarcinoma after distal pancreatectomy can be achieved.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Blood Transfusion. Carcinoma, Pancreatic Ductal / surgery. Critical Care. Cystadenocarcinoma, Mucinous / surgery. Cystadenoma, Mucinous / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Safety. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1976 Mar;42(3):173-7 [1259248.001]
  • [Cites] Br J Surg. 1993 Sep;80(9):1177-9 [8402126.001]
  • [Cites] Am J Surg. 1992 Jul;164(1):26-31 [1378243.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):147-57; discussion 157-8 [11992799.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):976-9 [1913121.001]
  • [Cites] Surgery. 1985 Jan;97(1):28-35 [2578229.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):946-52; discussion 952 [14675703.001]
  • [Cites] Surgery. 1992 May;111(5):489-94 [1317976.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):237-41 [11943118.001]
  • [Cites] Am Surg. 1989 Jan;55(1):21-5 [2913905.001]
  • [Cites] Ann Surg. 1977 Jan;185(1):52-7 [831636.001]
  • [Cites] Ann Surg. 1996 May;223(5):506-11; discussion 511-2 [8651741.001]
  • [Cites] J Trauma. 1991 Dec;31(12):1600-6 [1749029.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):397-402 [4005804.001]
  • [Cites] Arch Surg. 2000 Apr;135(4):409-14; discussion 414-5 [10768705.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):342-7; discussion 347-9 [8813262.001]
  • (PMID = 16137585.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Kamisawa T, Tu Y, Egawa N, Nakajima H, Tsuruta K, Okamoto A: Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol; 2005 Sep 28;11(36):5688-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas.
  • AIM: As intraductal papillary mucinous neoplasm (IPMN) has a favorable prognosis, associated malignancies have potential significance in these patients.
  • METHODS: Seventy-nine cases of IPMN were diagnosed by detection of mucous in the pancreatic duct during endoscopic retrograde pancreatography.
  • Histological diagnosis was confirmed in 30 cases (adenoma (n = 19) and adenocarcinoma (n = 11).
  • Other primary malignancies associated with IPMN, occurring in the prediagnostic or postdiagnostic period, were investigated.
  • They were found before (n = 15), at (n = 19) and after (n = 6) the diagnosis of IPMT.
  • Pancreatic cancer was synchronous with IPMN in two patients and metachronous in one (3 years after diagnosis of IPMN).
  • Development of other malignancies was related to age (71.9+/-8.2 vs 66.8+/-9.3, P<0.05), but not to gender or site of the tumor.
  • CONCLUSION: IPMN is associated with a high incidence of other malignancies, particularly gastric and colonic cancers.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Carcinoma, Pancreatic Ductal / complications. Colonic Neoplasms / complications. Esophageal Neoplasms / complications. Lung Neoplasms / complications. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237766.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4481489
  •  go-up   go-down


64. Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Tanizawa Y: Clinical results of extended lymphadenectomy and intraoperative radiotherapy for pancreatic adenocarcinoma. Hepatogastroenterology; 2007 Mar;54(74):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical results of extended lymphadenectomy and intraoperative radiotherapy for pancreatic adenocarcinoma.
  • The objective of this study was to clarify the surgical outcome after pancreatic resection with extended lymphadenectomy or intraoperative radiotherapy in patients with pancreatic adenocarcinoma.
  • METHODOLOGY: Between 1992 and 2002, 105 patients with pancreatic adenocarcinoma undergoing surgical resection were retrospectively analyzed.
  • Eighty-eight patients had invasive ductal adenocarcinoma and 17 had invasive intraductal papillary mucinous adenocarcinoma.
  • RESULTS: Patients with invasive intraductal papillary mucinous adenocarcinoma had a similar prognosis to those with invasive ductal adenocarcinoma.
  • CONCLUSIONS: Neither extended lymphadenectomy nor intraoperative radiotherapy showed a survival advantage in patients with resectable pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiotherapy. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / radiotherapy. Carcinoma, Pancreatic Ductal / surgery. Lymph Node Excision / methods. Pancreatectomy / methods. Pancreatic Neoplasms / radiotherapy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523323.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


65. Sheng Z, Wang J, Dong Y, Ma H, Zhou H, Sugimura H, Lu G, Zhou X: EphB1 is underexpressed in poorly differentiated colorectal cancers. Pathobiology; 2008;75(5):274-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression levels of EphB1 in colon cancer cell lines and human colorectal carcinoma specimens were determined and association of EphB1 expression with clinicopathological parameters was analyzed.
  • However, there is marked variability in the expression of the EphB1 transcripts and proteins among colorectal carcinoma specimens.
  • Reduced expression of EphB1 in colorectal cancers more often occurred in poorly differentiated and mucinous adenocarcinomas than in well- and moderately differentiated adenocarcinomas.
  • Further, cancer cells with a low level of EphB1 protein showed more invasive power.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Receptor, EphB1 / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18931529.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphB1
  •  go-up   go-down


66. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


67. Bakalianou K, Liapis A, Iavazzo C, Salakos N, Kalampokas T, Kondi-Pafiti A: Primary mixed epithelial and germ cell tumors of the ovary. Two case reports and literature review. Eur J Gynaecol Oncol; 2010;31(6):717-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mixed epithelial and germ cell tumors of the ovary. Two case reports and literature review.
  • Two cases of mixed germ cell and epithelial primary ovarian tumors which developed in women 47 and 57 years of age are reported.
  • In both cases, large teratomas measuring 20 and 21 cm were observed in combination with carcinoids and malignant mucinous neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoid Tumor / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319527.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


68. Rice GE, Edgell TA, Autelitano DJ: Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J Exp Clin Cancer Res; 2010;29:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Area Under Curve. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / pathology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Membrane Proteins / blood. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 1999 Nov;73(5):2084-92 [10537068.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88 [20082099.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):399-402 [11555720.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):579-85 [12592373.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84 [14734480.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Arthritis Rheum. 2004 May;50(5):1420-9 [15146411.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Eur J Biochem. 1989 Dec 22;186(3):733-40 [2558016.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Sep 14;171(2):603-9 [2403350.001]
  • [Cites] Dev Biol. 1993 Oct;159(2):392-402 [8405666.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1584-90 [7520350.001]
  • [Cites] Jpn J Cancer Res. 1997 Jan;88(1):64-71 [9045898.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1814-9 [9135027.001]
  • [Cites] Obstet Gynecol. 1997 Aug;90(2):285-90 [9241309.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 9;251(1):111-6 [9790916.001]
  • [Cites] Seikagaku. 1998 Nov;70(11):1315-25 [9889592.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12474-9 [10212223.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3796-805 [15867376.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4993-7 [15958538.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6116-26 [16144910.001]
  • [Cites] Lab Invest. 2006 Jul;86(7):645-53 [16619002.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Oct;291(4):G735-43 [16959957.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):757-62 [17506984.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):60-7 [17379400.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Trends Mol Med. 2008 Jun;14(6):261-7 [18487087.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Sci. 2008 Oct;99(10):2070-4 [19016768.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5 [19285648.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):15868-75 [11340082.001]
  • (PMID = 20525245.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Cytokines; 0 / MUC16 protein, human; 0 / Membrane Proteins; 0 / Proteins; 137497-38-2 / midkine; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC3161349
  •  go-up   go-down


69. Yantiss RK, Panczykowski A, Misdraji J, Hahn HP, Odze RD, Rennert H, Chen YT: A comprehensive study of nondysplastic and dysplastic serrated polyps of the vermiform appendix. Am J Surg Pathol; 2007 Nov;31(11):1742-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated a study group of 56 serrated polyps, a control group of 17 mucinous cystadenomas, and 4 adenocarcinomas with adjacent serrated polyps of the appendix to better understand their pathogenesis.
  • Loss of MLH-1 (25%) or MGMT (50%) expression and BRAF or KRAS mutations (50%) were inconsistently present in adenocarcinomas and were not identified in combination in any cases.
  • We conclude that molecular features of the "serrated neoplastic pathway" are present with similar frequencies among dysplastic and nondysplastic serrated appendiceal polyps and are not highly prevalent in adjacent carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Adenomatous Polyps / pathology. Appendix / pathology. Cecal Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Cystadenoma, Mucinous / pathology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / analysis. Adult. Aged. Aged, 80 and over. Cell Proliferation. DNA Modification Methylases / analysis. DNA Repair Enzymes / analysis. Female. Gene Expression Regulation. Humans. Ki-67 Antigen / analysis. Male. Microsatellite Instability. Middle Aged. Mucous Membrane / pathology. MutS Homolog 2 Protein / analysis. Mutation. Neoplasm Invasiveness. Nuclear Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. Retrospective Studies. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Proteins / analysis. beta Catenin / analysis. beta Catenin / genetics. ras Proteins / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2008 Jan;32(1):175. Hahn, Hejin P [added]
  • (PMID = 18059232.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CTNNB1 protein, human; 0 / KRAS protein, human; 0 / Ki-67 Antigen; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 3.6.5.2 / ras Proteins; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


70. Takahashi S, Homma H, Akiyama T, Mesawa S, Hirata K, Kogawa K, Takanashi K, Ishiwatari H, Kawano Y, Hayashi T, Takada K, Miyanishi K, Kato J, Niitsu Y: [A case of intraductal papillary mucinous neoplasm with internal pancreatic fistula causing left ureteral obstruction]. Nihon Shokakibyo Gakkai Zasshi; 2007 Aug;104(8):1236-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of intraductal papillary mucinous neoplasm with internal pancreatic fistula causing left ureteral obstruction].
  • A 75-year-old man had been admitted to another hospital because of left abdominal pain, and was given a diagnosis of left hydronephrosis and acute pancreatitis.
  • ERCP and MRCP showed focal irregular narrowing of the pancreatic duct of unknown cause, and we decided that an internal pancreatic fistula due to pancreatitis had induced left ureteral obstruction, caused by a protein plug or alcohol.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Carcinoma, Pancreatic Ductal / complications. Pancreatic Fistula / complications. Pancreatic Neoplasms / complications. Ureteral Obstruction / etiology
  • [MeSH-minor] Acute Disease. Aged. Humans. Male. Pancreatitis / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675827.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Mundhenke C, Weigel MT, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W, Maass N: Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol; 2008 Dec;134(12):1397-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Benzamides. Carboplatin / administration & dosage. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Paclitaxel / administration & dosage. Piperazines / administration & dosage. Proto-Oncogene Proteins c-abl / genetics. Proto-Oncogene Proteins c-abl / metabolism. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / administration & dosage. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3312-22 [11454878.001]
  • [Cites] Biotechniques. 1995 Oct;19(4):640-9 [8777059.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4217-26 [15483033.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):78-86 [15047217.001]
  • [Cites] J Cell Physiol. 1998 Dec;177(3):426-38 [9808151.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36 [12528770.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):2014-22 [14701673.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23432-40 [12697749.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):699-709 [12939459.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):126-31 [16271384.001]
  • [Cites] J Pathol. 2002 Apr;196(4):467-77 [11920744.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3319-26 [10955819.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):385-94 [15617027.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1246-50 [11350890.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10 (2):681-90 [14760091.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):897-908 [14871965.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):122-31 [17169414.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):407-16 [10769688.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1014-8 [12130516.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1086-91 [11159541.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1087-92 [11861387.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17(4):784-8 [17343607.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):768-76 [10842189.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3084-92 [10963636.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2060-9 [16331269.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2048-55 [15583695.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2929-34 [11306470.001]
  • (PMID = 18465140.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


72. Choi DH, Kim S, Rimm DL, Carter D, Haffty BG: Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J; 2005 Sep-Oct;11(5):404-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Neoplasms, Ductal, Lobular, and Medullary / chemistry. Protein Array Analysis
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / metabolism. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Time Factors. Tumor Suppressor Protein p53 / analysis. Women's Health

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259871.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


73. von Herbay A, Arens N, Friedl W, Vogt-Moykopf I, Kayser K, Müller KM, Back W: Bronchioloalveolar carcinoma: a new cancer in Peutz-Jeghers syndrome. Lung Cancer; 2005 Feb;47(2):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchioloalveolar carcinoma: a new cancer in Peutz-Jeghers syndrome.
  • Besides gastrointestinal hamartomatous polyposis and melanin spots in the skin and mucosa, patients with the Peutz-Jeghers syndrome (PJS) have repeatedly been observed with a variety of tumours, including lung cancer.
  • Herein, bronchioloalveolar carcinoma (BAC) of mucinous type is reported in a 22-year old male PJS patient with a novel germline frameshift insertion in exon 2 at codon 118 of the STK11 gene.
  • This observation supports the hypothesis that STK11 is a tumour suppressor gene which is involved in the development of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / etiology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Chromosomes, Human, Pair 19. Lung Neoplasms / etiology. Lung Neoplasms / genetics. Peutz-Jeghers Syndrome / complications. Peutz-Jeghers Syndrome / genetics. Protein-Serine-Threonine Kinases / genetics

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15639728.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


74. Obenauer S, Sohns C, Werner C, Grabbe E: Impact of breast density on computer-aided detection in full-field digital mammography. J Digit Imaging; 2006 Sep;19(3):258-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study was to evaluate the performance of a computer-aided detection (CAD) system in full-field digital mammography (Senographe 2000D, General Electric, Buc, France) in finding out carcinomas depending on the parenchymal density.
  • A total of 226 mediolateral oblique (MLO) and 186 craniocaudal (CC) mammographic views of histologically proven cancers were retrospectively evaluated with a digital CAD system (ImageChecker V2.3 R2 Technology, Los Altos, CA, USA).
  • Malignant tumors were detected correctly by CAD in MLO view in 84.85% in breasts with parenchymal tissue density of the American College of Radiology (ACR) type 1, in 70.33% of the ACR type 2, in 68.12% of the ACR type 3, and in 69.70% of the ACR type 4.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Mammography. Radiographic Image Enhancement. Radiographic Image Interpretation, Computer-Assisted
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Calcinosis / pathology. Calcinosis / radiography. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radiography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. False Positive Reactions. Female. Germany. Hemangiosarcoma / pathology. Hemangiosarcoma / radiography. Humans. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity


75. Schmidt CM, Lillemoe KD: IPMN-controversies in an "epidemic". J Surg Oncol; 2006 Aug 1;94(2):91-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatectomy / contraindications. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Humans. Pancreatic Ducts / pathology. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847916.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] United States
  •  go-up   go-down


76. Nagano H, Koneri K, Honda K, Murakami M, Hirono Y, Maeda H, Goi T, Iida A, Katayama K, Yamaguchi A: Biliopancreatic fistula and abscess formation in the bursa omentalis associated with intraductal papillary mucinous cancer of the pancreas. Int J Clin Oncol; 2009 Oct;14(5):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliopancreatic fistula and abscess formation in the bursa omentalis associated with intraductal papillary mucinous cancer of the pancreas.
  • We describe an unusual case of biliopancreatic fistula, free perforation, and subsequent abscess formation within the lesser peritoneal sac associated with intraductal papillary mucinous carcinoma (IPMC).
  • Abdominal computed tomography (CT) revealed findings consistent with an intraductal papillary mucinous neoplasm (IPMN) of the pancreas, accompanied by abscess formation in the bursa omentalis.
  • Pathological examination revealed IPMN with patchy, scattered carcinoma of the pancreatic head and uncinate process with the formation of a biliopancreatic fistula.
  • [MeSH-major] Abdominal Abscess / etiology. Adenocarcinoma, Mucinous / complications. Biliary Fistula / etiology. Carcinoma, Pancreatic Ductal / complications. Carcinoma, Papillary / complications. Pancreatic Fistula / etiology. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1993 Dec;90(12):3081-9 [8283821.001]
  • [Cites] Am J Gastroenterol. 1985 Apr;80(4):287-9 [3984999.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1164-7 [11020905.001]
  • [Cites] Endoscopy. 2004 Feb;36(2):186-9 [14765321.001]
  • [Cites] Gastroenterology. 1977 Dec;73(6):1410-2 [913983.001]
  • [Cites] JOP. 2005 May 10;6(3):255-9 [15883476.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):101-6 [15361642.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Dec;26(12 ):1172-4 [12520206.001]
  • (PMID = 19856058.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Wolf EM, Vieth M, Watanabe H, Spuller E, Leskowschek H, Langner C: Early mucinous colorectal adenocarcinoma--mucosal type. Endoscopy; 2010;42 Suppl 2:E236-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early mucinous colorectal adenocarcinoma--mucosal type.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Sigmoid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931458.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA, Johnson SW: Gene expression profiling of human ovarian tumours. Br J Cancer; 2006 Oct 23;95(8):1092-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One consisted predominantly of benign tumours, one contained mostly malignant tumours, and one was comprised of a mixture of borderline and malignant tumours.
  • Using two supervised approaches, we identified a set of genes that distinguished the benign, borderline and malignant phenotypes.
  • Hierarchical clustering of these data resulted in two major groups, one benign and one malignant, with the borderline tumours interspersed between the two groups.
  • These results indicate that borderline ovarian tumours may be classified as either benign or malignant, and that this classifier could be useful for predicting the clinical course of borderline tumours.
  • Immunohistochemical analysis also demonstrated increased expression of CD24 antigen in malignant versus benign tumour tissue.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechniques. 2000 Sep;29(3):548-50, 552-4, 556 passim [10997270.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):626-9 [9485012.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):521-6 [11179481.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):65-70 [11299791.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1158-65 [11378347.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61 [11906548.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1215-21 [12368195.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):289-302 [12569552.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):439-44 [12688312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5778-82 [12732717.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):240-7 [12819390.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4906-13 [14581365.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1599-604 [14583755.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] J Exp Ther Oncol. 2003 Nov-Dec;3(6):297-304 [14678518.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):183-92 [14716744.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):305-14 [9633842.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):372-80 [9633850.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):686-92 [14760385.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1045-52 [14983501.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):364-75 [14996858.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1620-6 [15083195.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):735-48 [15150282.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1663-7 [1689846.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1810-20 [8383580.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):247-52 [8314147.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] J Cell Biol. 1997 May 19;137(4):899-908 [9151692.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1535-8 [10789720.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • (PMID = 16969345.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM040711; United States / NIGMS NIH HHS / GM / GM40711; United States / NCI NIH HHS / CA / U01-CA85059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Calcium-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / SPARCL1 protein, human
  • [Other-IDs] NLM/ PMC2360705
  •  go-up   go-down


79. Iwuagwu OC, Jameel JK, Drew PJ, Hartley JE, Monson JR: Primary carcinoma of the appendix - Hull series. Dig Surg; 2005;22(3):163-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the appendix - Hull series.
  • BACKGROUND: Appendiceal carcinoma (AC) is a rare entity that does not have a well-defined treatment strategy.
  • At presentation, most patients are clinically thought to have appendicitis and the diagnosis is made only by formal histology.
  • Once the diagnosis of AC is made, patients are treated by various strategies including surgery, chemotherapy depending on nodal status of the disease.
  • METHODS: Between 1982 and 2002, 10 patients with primary AC were seen.
  • We did not include patients with primary carcinoid tumours or secondary adenocarcinoma.
  • Complete follow-up information was available with a median follow-up time of 56 months, with a range of 12-168 months.
  • Five patients survived at least 4 years from the time of diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Appendiceal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16037676.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


80. Chen CQ, Fang LK, Ma JP, Cai SR, Dong WG, Huang YH, He YL, Zhan WH: [Regression analysis of the characteristics and outcome of colorectal cancer 1995 - 2007]. Zhonghua Yi Xue Za Zhi; 2010 Jul 13;90(26):1804-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients under age 40 had a higher percentage of poor differentiation (33.5%) and mucinous carcinoma (16.7%).
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979822.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


81. Jung JY, Song MH, Park YS, Jo YJ, Kim SH, Jun DW, Kim DH, Lee WM: [A case of mucinous noncystic carcinoma of the pancreas]. Korean J Gastroenterol; 2008 Mar;51(3):204-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of mucinous noncystic carcinoma of the pancreas].
  • Mucinous (colloid) carcinoma is defined as pools of stromal extracellular mucin containing scanty, floating carcinoma cells.
  • However, mucinous noncystic carcinoma of the pancreas (MNCC) is uncommon, comprising between 1% and 3% of all carcinomas of the pancreas.
  • In the past, MNCC generally had been categorized together with ordinary ductal adenocarcinoma or misdiagnosed as mucinous cystadenocarcinoma or signet-ring cell carcinoma.
  • The new WHO classification lists MNCC as a variant of ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451696.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


82. Charfi L, Mrad K, Sellami R, Driss M, Sassi S, Abbes I, Ben Romdhane K: Invasive mucinous carcinoma arising within breast fibroadenoma. Pathologica; 2008 Jun;100(3):199-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive mucinous carcinoma arising within breast fibroadenoma.
  • Malignant neoplasms arising in the epithelial component of breast fibroadenomas are rare.
  • The most frequent types are lobular and ductal intra-epithelial carcinomas, with a minority of infiltrating carcinoma.
  • We report a case of 36-year-old patient with invasive mucinous carcinoma (30 x 30 mm) arising in a complex breast fibroadenoma (130 x 60 x 30 mm).
  • The patient is alive without disease five years later.
  • To the best of our knowledge, this is the first report of an invasive mucinous carcinoma arising within breast fibroadenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Fibroadenoma / pathology. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841829.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


83. Okada K, Furuuchi T, Tamada T, Sasaki T, Suwa T, Shatari T, Takenaka Y, Hori M, Sakuma M: Pancreatobiliary fistula associated with an intraductal papillary-mucinous pancreatic neoplasm manifesting as obstructive jaundice: report of a case. Surg Today; 2008;38(4):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatobiliary fistula associated with an intraductal papillary-mucinous pancreatic neoplasm manifesting as obstructive jaundice: report of a case.
  • We report a pancreatobiliary fistula caused by an intraductal papillary-mucinous pancreatic neoplasm (IPMN), manifesting as obstructive jaundice.
  • Endoscopic retrograde pancreatocholangiography showed a patulous papilla with mucin secretion.
  • Histologic examination revealed a pancreatobiliary fistula caused by intraductal papillary-mucinous carcinoma of the pancreas with mucin hypersecretion, an adenoma without interstitial infiltration, and isolated implantation of an IPMN in the bile duct mucosa around the fistula.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Biliary Fistula / complications. Carcinoma, Papillary / complications. Jaundice, Obstructive / etiology. Pancreatic Fistula / complications. Pancreatic Neoplasms / complications. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Aged. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Follow-Up Studies. Humans. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1993 Dec;90(12):3081-9 [8283821.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1985 Apr;82(4):685-90 [4021171.001]
  • [Cites] Rom J Gastroenterol. 2005 Jun;14 (2):169-72 [15990938.001]
  • [Cites] Am J Surg. 2000 May;179(5):349-51 [10930477.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):689-96 [8392902.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1164-7 [11020905.001]
  • [Cites] Arch Pathol Lab Med. 1995 Mar;119(3):197-8 [7887770.001]
  • [Cites] Endoscopy. 2004 Feb;36(2):186-9 [14765321.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):101-6 [15361642.001]
  • [Cites] World J Surg Oncol. 2005 Oct 19;3:70 [16232325.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):692-709 [8799417.001]
  • (PMID = 18368332.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


84. Kazakov DV, Suster S, LeBoit PE, Calonje E, Bisceglia M, Kutzner H, Rütten A, Mentzel T, Schaller J, Zelger B, Baltaci M, Leivo I, Rose C, Fukunaga M, Simpson RH, Yang Y, Carlson JA, Cavazza A, Hes O, Mukensnabl P, Vanecek T, Fidalgo A, Pizinger K, Michal M: Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast. Am J Surg Pathol; 2005 Jun;29(6):764-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast.
  • We present the largest series of mucinous carcinoma involving the skin, describing the histopathologic, immunohistochemical, electron microscopic, and cytogenetic findings.
  • In addition, we wished to reevaluate the differential diagnostic criteria for distinguishing primary mucinous carcinomas from histologically similar neoplasms involving the skin secondarily, and study some aspects of their pathogenesis.
  • We demonstrate that primary cutaneous mucinous carcinomas span a morphologic spectrum compatible to their mammary counterparts.
  • Most lesions seem to originate from in situ lesions that may represent, using mammary pathology terminology, ductal hyperplasia, atypical ductal hyperplasia, or ductal carcinoma in situ or a combination of the three.
  • The presence of an in situ component defines the neoplasm as primary cutaneous, but its absence does not exclude the diagnosis; although for such neoplasms, full clinical assessment is essential.
  • Mammary mucinous carcinoma involving the skin: all patients presented with lesions on chest wall, breast, axilla, and these locations can serve as clue to the breast origin.
  • Microscopically, cutaneous lesions were of both pure and mixed type, and this correlated with the primary in the breast.
  • Dirty necrosis was a constant histologic finding in intestine mucinous carcinomas involving the skin, and this feature may serve as a clue to an intestinal origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Intestinal Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897743.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y: CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas; 2009 Nov;38(8):e207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas.
  • OBJECTIVES: The rate of intraductal papillary mucinous neoplasm (IPMN) progression is much slower than that of invasive ductal adenocarcinomas.
  • The identification of a clinicopathological marker to distinguish IPMNs from ductal adenocarcinomas is important for understanding the molecular mechanisms of pancreatic cancer.
  • METHODS: We examined the expression pattern of the cell surface marker CD133, which has been used to identify putative cancer stem cells from solid tumors, in adult pancreatic ductal adenocarcinomas (n = 10) and IPMNs (n = 34).
  • CD133 expression was also observed in ductal adenocarcinomas.
  • In contrast, CD133 expression was not observed in the mucin-producing epithelial cells and carcinoma cells on IPMNs.
  • CONCLUSIONS: These results demonstrate that the expression of CD133 is down-regulated in IPMNs, suggesting that loss of CD133 expression might be a useful clinicopathological marker distinguishing IPMNs from ductal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Antigens, CD / biosynthesis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Glycoproteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pancreatic Ducts / chemistry. Pancreatic Ducts / pathology. Peptides. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786935.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


86. Shin SS, Armao DM, Shah M, Kim YH, Lee CH, Rubinas T, Brubaker LM, Semelka RC: Management of branch-duct intraductal papillary mucinous neoplasms of the pancreas: observation with MR imaging. Magn Reson Imaging; 2010 Dec;28(10):1440-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of branch-duct intraductal papillary mucinous neoplasms of the pancreas: observation with MR imaging.
  • PURPOSE: To evaluate the clinical outcomes of conservative management by observation with MRI of patients with branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs).
  • All patients were evaluated to search for evidence of malignant progression of disease.
  • The maximum diameter of BD-IPMNs ranged between 6 and 32 mm, with a mean of 12 mm.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Ductal / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20833500.001).
  • [ISSN] 1873-5894
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


87. Pillay N, Ramdial PK, Cooper K, Batuule D: Mucinous tubular and spindle cell carcinoma with aggressive histomorphology--a sarcomatoid variant. Hum Pathol; 2008 Jun;39(6):966-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous tubular and spindle cell carcinoma with aggressive histomorphology--a sarcomatoid variant.
  • Mucinous tubular and spindle cell carcinoma (MTSCC) is a recently described renal epithelial tumor.
  • The bland cytomorphology of the spindled component and low-grade behavior help in its differentiation from sarcomatoid renal carcinoma.
  • Sarcomatoid change has been reported in most histologic variants of renal cell carcinoma apart from MTSCC.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Aged. Biomarkers, Tumor / analysis. Cell Proliferation. Female. Humans. Immunohistochemistry. Mitosis. Necrosis. Nephrectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Jun;40(6):906-7 [19442792.001]
  • (PMID = 18400251.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Sweetser S, Vege SS, Clain JE, Topazian MD: Does splenic vein thrombosis predict invasive malignancy in side-branch intraductal papillary mucinous neoplasm (IPMN)? Am J Gastroenterol; 2008 Sep;103(9):2412-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does splenic vein thrombosis predict invasive malignancy in side-branch intraductal papillary mucinous neoplasm (IPMN)?
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Splenic Vein. Venous Thrombosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844637.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


89. Sahani DV, Lin DJ, Venkatesan AM, Sainani N, Mino-Kenudson M, Brugge WR, Fernandez-Del-Castillo C: Multidisciplinary approach to diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas. Clin Gastroenterol Hepatol; 2009 Mar;7(3):259-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach to diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas.
  • Intraductal papillary mucinous neoplasms have gained recognition in recent years as premalignant precursors to pancreatic cancer that enable early detection and often are found incidentally at imaging.
  • Accurate diagnosis and optimal, finely tuned management of these lesions are important and require collaboration across various disciplines, including radiology, endoscopy, surgery, and pathology.
  • Furthermore, issues of multifocality and increased predisposition of the pancreas to ductal adenocarcinoma must be addressed at follow-up evaluation.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / therapy. Pancreas / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121413.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


90. Pryor A, Means JR, Pappas TN: Laparoscopic distal pancreatectomy with splenic preservation. Surg Endosc; 2007 Dec;21(12):2326-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 12 laparoscopic distal pancreatic resections were attempted for three men and nine women with a mean age was 55.8 years (range, 33-74 years).
  • The final pathologic diagnosis included neuroendocrine tumors (n = 2), cystic serous (n = 4) and mucinous (n = 2) neoplasms, intraductal papillary mucinous neoplasm (IPMN) (n = 1), pancreatitis (n = 2), and adenocarcinoma (n = 1).

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Surg. 2000;17 (5):519-22 [11124560.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):766-72; discussion 772-4 [15531229.001]
  • [Cites] Am Surg. 1999 Jun;65(6):596-9 [10366217.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] J Pediatr Surg. 2002 Oct;37(10):1459-63 [12378454.001]
  • [Cites] J Vasc Interv Radiol. 2001 Feb;12 (2):209-14 [11265885.001]
  • [Cites] Clin Anat. 2004 Sep;17(6):497-502 [15300870.001]
  • [Cites] J Trauma. 2004 Apr;56(4):768-72; discussion 773 [15187739.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):149-58 [12170019.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2004 Apr;14(2):53-60 [15287601.001]
  • [Cites] J Trauma. 1991 Mar;31(3):385-8 [2002526.001]
  • (PMID = 17593458.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. King J, Kazanjian K, Matsumoto J, Reber HA, Yeh MW, Hines OJ, Eibl G: Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg; 2008 Sep;12(9):1548-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of these 125 patients, 27 (21.6%) had an islet cell tumor, 25 (20%) adenocarcinoma, 24 (18.4%) serous cystic neoplasm, 19 (15.2%) mucinous cystic neoplasm, 11 (8.8%) chronic pancreatitis, and eight (6.4%) intraductal papillary mucinous neoplasm.
  • DISCUSSIONS: With a median follow-up of 21 months, 10 (9%) of previously nondiabetic patients developed new onset diabetes.
  • Neither demographics, diagnosis, nor operative statistics impacted the risk of postoperative diabetes.
  • [MeSH-minor] Age Distribution. Aged. Analysis of Variance. Blood Glucose / analysis. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Laparoscopy / adverse effects. Laparoscopy / methods. Length of Stay. Male. Middle Aged. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Probability. Reference Values. Registries. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Distribution. Survival Analysis

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):758-68 [17955017.001]
  • [Cites] Surgery. 2007 May;141(5):619-25 [17462461.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):266-71 [15864637.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] World J Surg. 2003 May;27(5):595-8 [12715230.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):909-18; discussion 918-20 [17122616.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):890-8 [10816633.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Arch Surg. 2008 Feb;143(2):175-80; discussion 180-1 [18283143.001]
  • [Cites] Surgery. 1993 May;113(5):532-5 [8488471.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):573-82 [17414606.001]
  • [Cites] Metabolism. 2006 Jan;55(1):135-41 [16324932.001]
  • [Cites] J Am Coll Surg. 2007 Jul;205(1):52-9 [17617332.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):246-53 [17667503.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):69-76 [17592293.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1264-78; discussion 1278-9 [17114013.001]
  • [Cites] Mem Acad Chir (Paris). 1957 Nov 13-20;83(27-28):869-71 [13503655.001]
  • [Cites] World J Surg. 1998 May;22(5):494-8 [9564295.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):837-42 [15985241.001]
  • [Cites] Surgery. 2004 Sep;136(3):617-23 [15349110.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):715-6 [10873008.001]
  • [Cites] J Gastrointest Surg. 2007 Jun;11(6):730-2 [17530335.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):190-6 [12555295.001]
  • [Cites] World J Surg. 2001 Apr;25(4):452-60 [11344398.001]
  • [Cites] Br J Surg. 1990 May;77(5):541-4 [2354339.001]
  • [Cites] Br J Surg. 1996 Dec;83(12):1711 [9038547.001]
  • (PMID = 18543045.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / P01 AT003960; United States / NCI NIH HHS / CA / R21 CA124609
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


92. Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM: Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology; 2009 Sep;55(3):346-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
  • AIMS: Histological grade is one of the most important prognostic factors in breast carcinomas, but poorly differentiated neoplasms still have quite heterogeneous biological behaviour, since they can be genetically classified as basal-like, HER2+ or even luminal.
  • The aim was to analyse the frequency of oestrogen receptor (ER), progesterone receptor (PR) and HER2 expression profiles among breast carcinomas with <10% tubular formation, and their correlation with classic prognostic factors.
  • The histological features of triple-negative and HER2+ carcinomas overlap.
  • The only difference was the expression of basal cytokeratins (basal CK), which was more frequent among triple-negative carcinomas.
  • CONCLUSIONS: Group 1 and 2 tumours (ER+ and/or PR+ tumours with or without HER2 expression) were not statistically different, suggesting that poorly differentiated carcinomas with hormone receptors correspond to the luminal B type of tumour.
  • Among poorly differentiated breast carcinomas, the classic profile associated with basal-CK identifies distinct subtypes equivalent to those seen by genetic classification.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Keratins / metabolism. Middle Aged. Necrosis. Prognosis. Retrospective Studies. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723150.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


93. Wang ZH, Guo J, Chen Z, Li CZ, Sheng LJ, Zhou DG, Liu B, Liu J, Wang QC, Zhang EN: [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2008 May;30(5):389-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leukopenia / chemically induced. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Remission Induction. Taxoids / administration & dosage. Taxoids / adverse effects. Vomiting / chemically induced. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953843.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Phillips V, Kelly P, McCluggage WG: Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol; 2009 Mar;28(2):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.
  • There are several morphologic types of ovarian carcinoma.
  • It has been shown that p16 is overexpressed in high-grade serous carcinoma but there has been little detailed comparison of p16 expression in the common types of ovarian carcinoma.
  • The aim of this study was to compare p16 expression in ovarian carcinomas of serous, endometrioid, clear cell, and mucinous type with a view to ascertaining whether high expression in a primary ovarian carcinoma is specific for a serous neoplasm.
  • We included problematic cases, which are difficult to type, such as poorly differentiated and undifferentiated carcinomas and serous carcinomas with clear cells.
  • Cases of ovarian high-grade serous carcinoma (n=38), endometrioid carcinoma (n=15), clear cell carcinoma (n=12), and mucinous carcinoma (n=10) were stained with p16.
  • Serous carcinomas typically exhibited high p16 expression; there was statistically significant higher p16 expression in serous carcinomas compared with the other morphologic types.
  • There was high p16 and WT1 expression in most undifferentiated carcinomas and in serous carcinomas with clear cells, suggesting that these represent variants of serous carcinoma.
  • We have demonstrated that p16 is highly expressed in high-grade serous and undifferentiated carcinomas compared with other morphologic types of ovarian carcinoma.
  • This may be useful, in conjunction with WT1, in the classification of problematic neoplasms. p16 may be involved in the pathogenesis of high-grade ovarian serous carcinomas, possibly through inactivation of retinoblastoma protein.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / metabolism. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188815.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / WT1 Proteins
  •  go-up   go-down


95. Baiocchi GL, Portolani N, Missale G, Baronchelli C, Gheza F, Cantù M, Grazioli L, Giulini SM: Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications. World J Surg Oncol; 2010;8:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications.
  • BACKGROUND: Intraductal papillary mucinous neoplasms (IPMNs) are increasingly recognized entities, whose management remains sometimes controversial, due to the high rate of benign lesions and on the other side to the good survival after resection of malignant ones.
  • Total pancreatectomy was performed in 46% of the cases; in situ and invasive carcinoma were recognized in 15.4% and 38.4% of the cases, respectively.
  • One only patients with nodal metastases died 16 months after the operation for disease progression, while 91.6% of the operated patients are disease free.
  • Out of the 27 not resected patients, 2 out of 4 presenting a lesion at high risk for malignancy died, while the remaining are in good conditions and disease free, with a mean follow-up of 31 months.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatectomy. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):181-93 [10952400.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):701-7 [12397279.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1981-5 [9951851.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Endoscopy. 2006 Jun;38 Suppl 1:S40-7 [16802222.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):304-7 [17693271.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9 [18043094.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 20374620.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2858722
  •  go-up   go-down


96. Ghaneh P, Neoptolemos J: A new approach to managing intraductal papillary mucinous pancreatic neoplasms. Gut; 2007 Aug;56(8):1041-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new approach to managing intraductal papillary mucinous pancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):326-31 [16333703.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Surgery. 2006 Jun;139(6):749-54 [16782429.001]
  • [Cites] World J Surg. 2006 Oct;30(10):1909-14; discussion 1915 [16850142.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):689-96 [8392902.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1451-68; discussion 1468-70 [16284127.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1650-7 [16311856.001]
  • [Cites] Hum Pathol. 2006 Feb;37(2):212-7 [16426922.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Feb;21(2):462-7 [16509876.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Am J Surg. 2006 Jun;191(6):823-6 [16720158.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1184-92 [15316318.001]
  • [Cites] Am J Gastroenterol. 1980 Jun;73(6):512-5 [7424873.001]
  • [Cites] Radiology. 1986 Dec;161(3):697-700 [3786719.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [CommentOn] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • (PMID = 17625140.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1955504
  •  go-up   go-down


97. Sasajima Y, Mikami Y, Kaku T, Kiyokawa T, Ohishi Y, Hamada T, Sasaki T, Fujita H, Moriya T, Kasamatsu T, Tsuda H: Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix. Histopathology; 2008 Oct;53(4):487-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


98. Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, Zhan WH: [Clinical features of colorectal mucinous adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep;12(5):487-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of colorectal mucinous adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).
  • METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.
  • The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).
  • Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).
  • CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.
  • Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742341.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Yang AD, Melstrom LG, Bentrem DJ, Ujiki MB, Wayne JD, Strouch M, Bell RH, Rao SM, Talamonti MS: Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience. Surgery; 2007 Oct;142(4):529-34; discussion 534-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience.
  • PURPOSE: To evaluate the experience with pancreatectomy for intraductal papillary mucinous neoplasm (IPMN) at a single academic institution.
  • Nine patients had adenomas, 14 had borderline neoplasms, 10 had carcinoma in situ, and 9 had invasive carcinoma.
  • With a mean follow-up of 17 months, the 5-year disease-specific survival for patients with main duct involvement was 67%.
  • The 5-year disease-specific survival for patients with benign lesions was 100%, and 61% for patients with malignant lesions (P = .02).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / statistics & numerical data. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Databases, Factual. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950345.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Horrée N, van Diest PJ, Sie-Go DM, Heintz AP: The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol; 2007 Aug;38(8):1232-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators.
  • The aim of the study was to explore whether expression of proliferation and hypoxia-related proteins differs in the central parts and the invasive front in endometrial carcinomas.
  • Proliferation-associated proteins Ki67 and cyclin A; cell cycle regulators p16, p21, p53, cyclin D1, cyclin E, and cdk2; and hypoxia-inducible factor 1alpha and its downstream factors glucose transporter 1, carbonic anhydrase IX, and vascular endothelial growth factor were immunohistochemically stained in paraffin-embedded specimens from endometrioid (n = 33), mucinous (n = 1), and serous (n = 5) endometrial carcinomas.
  • Endometrial carcinomas clearly show an invasive front that is characterized by higher proliferation and progressive derailment of the cell cycle regulators cyclin E, p16, and cdk2, but not by an increased hypoxic response.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Cell Cycle Proteins / metabolism. Cell Proliferation. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Myometrium / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490724.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Ki-67 Antigen
  •  go-up   go-down






Advertisement